value innovation troper launna miehlegni regnirheob financial highlight amount million eur indicate change net sale region america europe asiaaustraliaafrica aaa business human pharma animal health biopharmaceutical contract manufacturing sale research development expense personnel expense average number employee operate income operating income net sale group profit group profit net sale group equity investment tangible asset depreciation tangible asset product human pharma net sale jardiance ofev family million eur million eur summary report trajenta spiriva jentadueto million eur million eur product animal health net sale nexgard frontline million eur million eur ingelvac heartgard circoflex flexcombo million eur million eur annual reportcontent core leitbild shareholder perspective key aspect corporate body group management report information group report economic position report opportunitie risk report expect development consolidate financial statement overview select consolidated company consolidate balance sheet consolidate profit loss statement consolidate cash flow statement statement change group equity note consolidate financial statement independent auditor report product portfolio human pharmaceutical respiratory disease cardiovascular metabolic disease oncology disease central nervous system infectious disease animal health livestock swine livestock cattleruminant livestock poultry veterinary public health vph companion animal horses companion animal pet company make new well medicine human animal heart mission create breakthrough therapy change live independent familyowne boehringer ingelheim freedom pursue longterm vision look ahead identify health challenge future target area need good worldleading researchdriven biopharmaceutical company employee create value innovation daily business area human pharma animal health biopharma ceutical contract manufacturing boehringer ingelheim achieve net sale billion eur significant investment billion eur rd drive innovation enable generation medicine save life improve quality life realize scientific opportunity embrace power partnership diversity expert lifescience community work accelerate delivery medical breakthrough transform live patient generation come boehringer ingelheim annual report shareholder perspective company shareholder perspective year pharmaceutical industry able demonstrate contribution society month s declaration pandemic see approval vaccine collaborative effort company provide tool protect vulnerable group importantly pharmaceutical industry maintain supply medicine unrelated covid continue work innovative medicine despite logistical production challenge concern few preventive screening checkup examination perform patient avoid visit medical center boehringer ingelheim invest substantially mitigate effect pandemic patient employee partner business allow medicine continue available patient animal despite covidrelated supply challenge time company show significant progress purse ambition develop breakthrough therapy human animal successful year employee show true agility facing challenge continue extraordinary thing difficult circumstance ensure supply muchneede medicine human animal advance medical progress continuously seek solution target area unmet medical need people boehringer ingelheim key strengthen longterm competitiveness behalf shareholder committee like thank support outside boehringer ingelheim extraordinary commitment sign christian boehringer chairman shareholder committeethe board manage director michel pairet carinne brouillonhubertus von baumbach michael schmelmer jean scheftsik de szolnok boehringer ingelheim annual report key aspect purpose transform live drive force decade excep tion successful delivering promise year improve life patient human animal alike lead gratify performance organization business area able manage effect covid pandemic operation pandemic show important pharmaceutical research medical progress societal safety innovation key driver transform life continue increase investment research development longterm commitment innovate unmet medical need prove value strong pipeline promise project stage clinical preclinical development break therapy designation grant fda testament strate gy right fourth breakthrough therapy designation follow february enable high engagement employee support broad network partner business unit record profitable growth year human pharma acceleration portfolio continue receive priority review immu nology medication fast track designation treatment nonalcoholic fatty liver disease innovative medication show growth lead jardiance ofev treatment reach seven million people worldwide company key aspect animal health good year sale competitive market like human pharma focus lie research develop product transform life animal strengthen capability increase investment grow pipeline product livestock companion animal continue optimize build strong base global research production marketing vienna austria inaugurate additional facility biopharmaceutical production network significantly increase production capacity mammalian bacteria base technology milestone investment allow meet grow internal pipeline demand production demand customer strongly commit bioxcellence brand year celebrate year anniversary make health social entrepreneur initiative green environmental footprint program seeing impact sustainable development activity help improve environment live human animal decide step investment broaden commitment focus umbrella sustainable development generation bring global sustainability initiative human animal health community environment decisive success factor personal engagement individual employee contribute share purpose transforming live human animal fact manage second year pandemic fill great gratitude partner sign sign sign hubertus von baumbach carinne brouillon michel pairet sign sign jean scheftsik de szolnok michael schmelmer boehringer ingelheim annual report corporate body shareholder committee christian boehringer chairman shareholders committee christoph boehringer erich von baumbach isabel boehringer dr mathias boehringer prof dr dr andreas barner company corporate body board manage director advisory board hubertus von baumbach dr nikolaus von bomhard chairman board manage director chairman advisory board chairman supervisory board carinne knochebrouillon mnchener rckversicherungsgesellschaft ag member board manage director human pharma dr hagen duenbostel chief executive officer ceo kws se dr michel pairet member board manage director dr frank mastiaux innovation chief executive officer enbw energie badenwrttemberg ag jean scheftsik de szolnok member board manage director jan rinnert animal health chairman board manage director ceo heraeus hold gmbh michael schmelmer member board manage director finance group functionsdiabete mellitus island langerhans human pancreasgroup management report information group group business model research development production employee report sustainable development generation report economic position macroeconomic environment earning position development business financial position net asset position report opportunitie risk opportunitie risk management individual risk overall statement risk situation report expect development troper tnemeganam puorg stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report group management report information group group business model boehringer ingelheim develop breakthrough therapy transform life today ge neration come independent familyowned pursue longterm vision identify tomorrow challenge seek solution target area unmet medical need capture purpose transforming live generation inspire significant difference human animal live boehringer ingelheim stand innovation year world lead company sector germany researchfocuse company human pharma business mainstay activity account share overall sale business area underpin innovative portfolio case product standard treatment medicine research focus cardiovascular metabolic disease oncology respiratory disease immunology disease central nervous system cns retinal health jardiance jardiance medicine treatment type diabetes reduce risk car new indication diovascular disease type diabetic preexist cardiovascular condition heart failure group big sell human pharma product consecutive year addition public health authority fda award jardiance breakthrough therapy designation btd extend use treatment heart failure medicine award new indication eus approval use treatment heart failure reduce ejection fraction hfref approval paraguay treatment heart failure preserve ejection fraction hfpef ofev treatment rare respiratory disease idiopathic pulmonary fibrosis ipf increasingly net sale business human pharma million eur animal health group million eur biopharmaceutical million eur contract manufacturing million eur sale million eur group management report information group net sale region million eur americas europe asiaaustraliaafrica aaa indication systemic sclerosis interstitial lung disease sscild registered strong growth product play significant role boehringer ingelheim success spiriva treatment chronic obstructive pulmonary disease copd asthma trajenta treatment type diabetes pradaxa prevent stroke patient atrial fibrillation prevention treatment thromboembolic disorder animal health business boehringer ingelheim significant provider vaccine therapeutic portfolio include product pet horse livestock swine ru minants poultry core brand nexgard follow frontline heartgard foundation success pet segment swine segment establish swine vaccine ingelvac circoflex treat porcine circovirus type important component company product portfolio biopharmaceutical activity comprise manufacture human pharmaceutical product actilyse metalyse praxbind world lead provider process development commercial production biopharmaceutical thirdparty industrial customer sale mainly comprise discontinue operation stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report financial year achieve majority sale america europe regions asiaaustraliaafrica aaa region include country china strategic significance group future development make sale research development goal research develop innovative medicine therapie treatment disease satisfactory treatment available major emphasis development medicine therapy prevent detect treat chronic disease aim relevant contribution area need treatment high human pharmaceutical segment field animal health global research network employ average people billion eur present country central facility germany biberach ingelheim rhein invest rd usa ridgefield connecticut duluth georgia st joseph missouri austria vienna japan kobe france lyon china shanghai activity continue expand renew exist product portfolio order safeguard group organic longterm growth accordingly considerably increase research development rd expense recent year past year growth outpace revenue trend total billion eur invest research development new medicine level correspond group net sale research development expense human pharma amount billion eur research development expense million eur net sale human pharma expense million eur human pharma net sale animal health expense million eur animal health net sale average number employee investment tangible asset million eur investment infrastructure group management report information group research rely longestablished relationship academic public research institution biotech company pharmaceutical company scientific field collaborate project academic institution span continent expand rd portfolio supplementary cooperation license agreement acquisition company research activity highly productive competitive human pharma aim source new molecule pipeline acquisition party high scientific standard business development relationship forge time early investment boehringer ingelheim venture fund play key role success boehringer ingelheim confirm attractiveness partner new acqui innovation network sition partnership human pharma business complete acquisition expand nbetherapeutics ag start year swiss biotech company supplement research activity innovative platform development antibodydrug con jugate pipeline complete acquisition contract manufacturer labor dr merk kollegen gmbh company subsequently rename boehringer ingelheim therapeutic gmbh important component research activity field immunooncology strengthen activity field oncology significantly step past year acquisition abexxa biologics inc sep tember research collaboration establish aim develop new antibody target cancerspecific protein expand portfolio partnership past financial year work wellknown lieber institute brain develop ment research new method treat neuropsychiatric disease enter collaboration twist bioscience corporation headquarter san francisco collaboration objective utilize twist proprietary antibody library identify potential antibody candidate therapeutic area establish longterm partnership animal health business petmedix ltd strong partner antibodybase therapy pet british company proprietary innovative platform enable rapid development antibodie longterm co operation lifebit biotech ltd provider biomedical datum analysis aim utilize ai platform order rapidly identify global outbreak infectious disease report early stage pursue basic research threeyear cooperation agreement google field quantum compute digital transformation strategy partnership aim harness computing power new technology service boehringer ingelheim research development pursue innovation rapid precise manner time conserve resource stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report rd site ah animal health hp human pharma bix bi x digital lab americas europe asia usa belgium china ames iowa ah evergem ah beijing ah athens georgia ah shanghai ah bi x germany colbert georgia ah taizhou ah biberach hp uluth georgia ah ingelheim rhein ah hp bi x japan f ulton missouri ah k atharinenhofrohrdorf ah kobe hp gainesville georgia ah ochsenhausen hp n orth brunswick new jersey ah ridgefield connecticut hp france joseph missouri ah lyon boreal ah lyon porte des alpes ah saintvulbas ah netherlands l elystad ah austria innsbruck hp vienna hp switzerland basel hp geneva hp group management report information group digital laboratory bi x focus establish new facility shanghai build new capability develop approve medical software product strategy bi x center excellence develop medical software product company abovementione structural development bi x organization bi x focus solution doctor patient human pharma business development digital product instance guard system help general practitioner good possible treatment decision type diabete patient base medical guideline boehringer ingelheim venture fund drive innovation strategic investment young company carry research earlystage science technology venture fund invest biotech startup company innovative concept technology potential provide groundbreake new therapeutic platform venture fund found company identify promise research project uni versitie academic institution establish venture fund asia alongside exist venture fund germany usa research institute molecular pathology imp vienna biomedical research insti tute wholly own group company fund boehringer ingelheim scientist approximately country imp conduct research molecular cellular mechanism form basis complex biological life process human disease imp lead institution kind late group leader receive prestigious grant award european research council erc success rate erc application period imp rank european research institute universi tie group leader elect member european molec ular biology organization embo open innovation platform opnmecom boehringer ingelheim contribute process scientific collaboration pharmaceutical world molecule preclinical stage currently available academic researcher world freeofcharge molecule enable new scientific finding eg field oncology boehringer ingelheim rd activity preclinical clinical research develop ment basis sustainable success group positive business development past year underpin organic process renew portfolio base research development activity inhouse rd supplement external cooperation partnership continue priority future high commitment innovation confirm year mean breakthrough therapy designation grant fda btd issue glycine transporter type inhibitor glyt bi contribution research treatment cognitive impairment induce schizophrenia month spesolimab receive btd classi fication follow orphan drug designation spesolimab treat rare inflammatory disease generalize pustular psoriasis gpp addition jardiance award btd connection extend use treatment patient heart failure stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report human pharma new promise human pharma business rd pioneer therapie active substance transform life patient significantly progress focus area cardio human pharma vascular metabolic disease oncology respiratory disease immunology disease portfolio central nervous system cns retinal health human pharma portfolio include compound development happen clinical trial project development pipeline end cardiometabolic disease phase metabolic modulator phase angiopoietin antibody phase food intake regulator phase hemodynamic modulator phase hemodynamic modulator phase transcient receptor potential channel inhibitor phase bi glpgcgr agonist nash phase ii bi glpgcgr agonist obesity phase ii bi hemodynamic modulator ckd phase ii tenecteplase china tissue plasminogen activator ais phase iii empagliflozin new indication sglt inhibitor ckd phase iii empagliflozin new indication sglt inhibitor hf post mi phase iii empagliflozin new indication sglt inhibitor chf registration oncology phase bhcd tcell engager phase dllcd tcell engager phase cdfap antagonist phase ezabenlimab pd antibody phase exon inhibitor phase kisima cancer vaccine phase kras gc inhibitor phase lrp antagonist phase mdmp antagonist phase mek inhibitor phase ror adc phase sirp antagonist phase soskra inhibitor phase sting agonist phase trailrcdh antibody phase group management report information group development pipeline end continue respiratory disease phase cysteine protease inhibitor phase bi antifibrotic ipf phase ii immunology phase bi kinase inhibitor cd phase ii spesolimab bi ilr antibody ppp phase ii spesolimab bi ilr antibody cd phase ii spesolimab bi ilr antibody hs phase ii spesolimab bi ilrantibody gpp registration central nervous system disease phase phosphodiesterase inhibitor phase digital therapy phase bi trpc inhibitor mdd phase ii bi trcp inhibitor bopd phase ii bi glyt inhibitor cia phase iii stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report development pipeline end continue retinal disease phase ischemia modulator phase neuronal damage modulator phase bi phase ii vegfang antibody wamd bi ischemia modulator dmi phase ii covid phase alteplase tpa cov iard phase iii indication abbreviations ais acute ischemic stroke cov covid induce acute mbc metastatic breast cancer atd atopic dermatitis iard respiratory distress syndrome mdd major depressive disorder bopd borderline personality disorder dmi diabetic macular ischemia mi myocardial infarction cd crohns disease gpp generalize pustular psoriasis nash nonalcoholic steatohepatitis chf congestive heart failure hf heart failure ppp palmoplantar pustulosis cia c ognitive impairment associate hs hidradentis suppurtiva tpa tissuetype plasminogen activator schizophrenia ipf idiopathis pulmonary fibrosis wamd moisture agerelate macular ckd chronic kidney disease degeneration partner project acquire asset study complete submission ongoing key pipeline advance dec dec cardiometabolic disease report positive result emperorpreserve phase iii trial adult heart failure preserve ejection fraction diabete base fda grant jardiance status breakthrough therapy reduce risk cardiovascu lar death hospitalization heart failure adult heart failure preserve ejection fraction addition announce positive result empulse trial adult hospital acute heart failure advance glpglucagon dual agonist inve tigate phase ii study individual diabete phase ii clinical trial adult liv ing obesity nonalcoholic steatohepatitis nash addition receive fast track designation fda adult nash oncology cancer disease devastate people diagnose love one partnership wide community support awareness education improve diagnosis care patient cancer work patient development process ensure new treatment meaningful difference reach patient fast need advance unique pipeline cancer cell di recte agent immunooncology therapy combination approach help win fight cancer group management report information group respiratory disease research development new therapeutic option people respiratory disease focus boehringer ingelheim ofev nintedanib treatment option idiopathic pulmonary fibrosis ipf slow decline lung function breakthrough pulmonary fibrosis therapy achieve lead new indication systemic sclerosisassociate interstitial lung disease sscild chronic fibrose interstitial lung disease progressive phenotype pfild building foundation ap proval country ofev approve treatment ipf country country sscild country pfild country approve treatment option sscild und pfild ongoing openlabel extension trial senscison inbuildon provide datum longtime safety efficacy nintedanib sscild pfild additionally inpedild study investigate dose safety profile nintedanib child adolescent despite advance therapy high unmet therapeutic need fibrose pulmonary disease investigate safety tolerability bi patient ipf clinical trial make good progress immunology immunological disease greatly impact live people live emotionally physi cally boehringer ingelheim dedicate discover develop firstoftheirkind thera pie inflammatory disease deep understand molecular pathway pioneer scientific breakthrough target repair prevent inflammatory disease skin gut joint spesolimab advanced investigational compound boehringer ingelheim immunology pipeline file marketing authorization fda ema chinese japanese authority treat patient flare generalize pustular psoriasis filing base positive phase ii data effisayil trial addition spesolimab grant breakthrough therapy designation china usa central nervous system boehringer ingelheim redefine mental health enable people thrive decade ago boehringer ingelheim embark research domain criterion rdoc inspire approach link behavior underlie neurobiology develop target therapy ease burden condition symptom example approach bi currently investigate clinical phase ii trial people live borderline personality major depressive disorder boehringer ingelheim initiat ed innovative connex phase iii clinical trial treatment cognitive impairment associate schizophrenia cia base successful phase ii trial cia fda grant breakthrough therapy designation bi novel glycine transport er glyt inhibitor indication stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report retinal disease retinal disease agerelate macular degeneration lead cause legal blind ness develop world current therapy retinal disease exist limited effectiveness real world significant unmet treatment need exist boehringer ingelheim continue develop advance retinal health pipeline clinical development new compound start potential treat wet agerelate macular degeneration geographic atrophy boehringer ingelheim transi tione potential treatment diabetic macular ischemia dmi phase ii trial work scientist complement collaboration academic patient organization alongside partnership biotech company covid researchdriven biopharmaceutical company utilize different area expertise find medical treatment covid initiate program develop new therapy option fully concentrate effort area development alteplase potential treatment covid patient severe breathing problem call acute respiratory distress syndrome ard currently compound investigate phase iii tristard phase iiiii study program discon tinued development bi patient hospitalize covid respiratory complication lack efficacy bi sarscov neutralize antibody lack coverage delta variant group management report information group follow table show relevant change current clinical study phase iii clinical trial phase change emperorpreserve nct phase iii phase iii study complete primary endpoint meet randomize doubleblind trial investigate publish new england journal medicine daily empagliflozin compare placebo empagliflozin demonstrate percent adult chronic heart failure preserve duction combine risk cardiovascular ejection fraction diabetes death hospitalization heart failure receive current standard care adult heart failure preserve ejection fraction empagliflozin reduce recurrent hospitalization heart failure percent significantly slow kidney function decline empulse nct multicenter run phase iii study complete primary endpoint meet domize doubleblind day superiority trial empulse phase iii study empagliflozin show evaluate effect clinical benefit safety significant clinical benefit adult stabilize tolerability daily oral empagliflozin mg acute heart failure hospital adult compare placebo initiate patient hospital hospitalize acute heart failure ize acute heart failure de novo decompen cent likely experience clinical benefit sated chronic hf stabilize treat empagliflozin pla cebo benefit consistent people new exist heart failure regardless ejection fraction diabete status effisayil nct week phase ii study complete primary endpoint meet phase ii trial investigate patient gpp publish new england journal medicine flare n patient randomize datum show spesolimab novel il treat intravenously mg antibody treatment effective rapidly spesolimab placebo primary endpoint treat adult patient generalize gpp physician global assessment gppga pus pustular psoriasis gpp experience flare tulation subscore visible pustule week key secondary endpoint gppga score clearalmost clear skin week connex phase iii clinical trial program phase iii start phase iii design assess safety efficacy bi improve cognition adult schizophrenia program comprise clinical trial phase iii randomized doubleblind placebocontrolle parallel group trial examine efficacy safety bi daily week treatment period patient schizophrenia tristard nct seamless phase iii start phase iii openlabel randomize parallelgroup phase iib iii trial evaluate efficacy safety daily intravenous alteplase day well available medical management stand ard care compare well available medical management adult covid acute respiratory distress syndrome ard primary objective trial time clinical improve ment hospital discharge stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report animal health area animal health boehringer ingelheim concentrate discovery devel opment treatment preventive therapy area medical need unmet effort great impact target therapeutic oncology immunology new chemical entity new method control counter resistance par asite new tool technology improve prevention infectious disease current portfolio include innovative vaccine antiparasitic protection live stock pet pharmaceutical product treatment chronic disease research increasingly incorporate new approach technology use stem cell monoclonal antibodie innovation strategy build scientific approach investigation cause mechanism disease multiple specie include animal human lead discovery new way mitigate cause intervene disease process broad approach enable work close cooperation human pharma colleague external partner area outside animal health strategic area infectious disease noninfectious disease parasiticides use strategy target solution broadly apply specie infectious disease eg vaccine focus area innovation mucosal immunity bacterial disease transboundary emerge disease noninfectious disease eg therapeutic focus collaboration human pharma grow capability key technology target external partnership parasiticides focus maintain leadership acceleration key discovery development program new molecule investment innovative technology long term include solution address sustainability research development site organize regional innovation center locate usa europe china organization support global innovation strategy en sure concentration critical mass expertise need deliver therapie customer key geographie specific site region serve focus competency particular segment overall strategy footprint strengthen local execution facil itate regional external network partnership synergies key strategic advantage boehringer ingelheim retain human pharma collaboration animal health division exploit synergy suc human pharma cessfully introduce product vetmedin semintra metacam aservo animal health equihaler additional promising compound pipeline expect innova tion connection particularly area therapeutic external partnership play key role demonstrate integration global stem cell technology nv later rename boehringer ingelheim veterinary medicine belgium company specialized stem cell therapy orthopedic immunological animal disease acquire cooperation lead stem cellbase animal health product articell forte approve european commission initiate number new strategic partnership include partnership petmedix platform generate canine therapeutic antibody use develop therapy immunemediate condition cancer allergy arthritis partner lifebit aid detect early report global infectious disease outbreak ai platform furthermore continue work key research institution friedrichloeffler institut pirbright institute oxford university innovation develop effective ap proache prevent african swine fever threaten swine industry worldwide group management report information group initiate research development clinical study worldwide award product authorization new regulatory approval clude nexgard combo eu canada extend flagship parasiticide brand cat nexgard spectra brazil new market broad spectrum product treat endo ectoparasites usa receive approval flex parvoprr combination vaccine effective reproductive failure cause common viral cause porcine reproductive failure globally obtain approval new product new area application expand geographic scope sale activ itie exist product additional important aspect research development activity help create value innovation production human pharma human pharma business globally active production facility responsible steady supply topquality medicine patient ongoing development company internal production facility strategic cooperation external manufacturer es tablishe modern flexible market supply network encompass entire value chain supplier start material worldwide logistic distribution finish phar maceutical product boehringer ingelheim production facility concentrate product strategically important company stateoftheart manufacture tech nologie time partnership external manufacturer add specialist technolo gy production network available inhouse expand production capacity standard technology product high capacity requirement far advanced term life cycle financial year global network include boehringer ingelheim plant country group biopharmaceutical facility facility manufacture pharmaceutical active substance produce medical device finish pharmaceutical product manufacture facility past year characterize unusual logistical challenge covid pandemic boehringer ingelheim able ensure steady supply medicine patient possible thank establishment key manufacturing step technologie multiple facility strengthen resilience concept link supply chain progress digitalization production network overall supply chain play key role ongoing development measure ensure security supply ongoing m plementation group supply chain strategy optimize value chain management supplier customer endtoend use digital automate process technology enable high level transparency efficient management global pro duction network supply chain delivery capacity patient care priority boehringer ingelheim company con sistently make important investment development transformation production capacity chemical pharmaceutical network ingelheim rhein headquar ter key investment flexible plant industrialization newly develop medicine initial market supply progress expansion production technology capacity pharmaceutical active substance fornovo italy facility pharmaceutical bulk drug sant cugat spain facility finish pharmaceutical product koropi greece yamagata japan facility ensure supply anti diabetic product jardiance particular pipeline product open stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report production facility ah animal health hp human pharma bio biopharmaceutical contract manufacturing americas europe asiaoceania brazil belgium great britain china itapecerica hp evergem ah pirbright ah nanchang ah paulnia ah shanghai hp bio denmark italy taizhou ah mexico kalundborg ah fornovo hp g uadalajara ah noventa ah indonesia germany xochimilco hp bogor hp biberach bio austria puerto rico dortmund hp vienna bio japan barceloneta ah ingelheim rhein hp yamagata hp spain usa france sant cugat hp new zealand athens georgia ah lyon ah auckland ah fremont california bio toulouse ah gainesville georgia ah st joseph missouri ah greece koropi hp grand lyon industrial biologic center lpa st priest lentilly jonage group management report information group biopharmaceutical largescale cell culture production building vienna facility represent milestone expansion capacity network newly develop product production facility global biopharmaceutical network cover activity increase demand actilyse metalyse animal health animal health product manufacture network production facility country addition company facility contract man ufacturer turn medicine boehringer ingelheim company product comprise vaccine pharmaceutical product nutraceutical traditional medicine supple animal health mente diagnostic product monitor solution include digital application production facility livestock monitoring link livestock owner veterinarian opti country mization company production network continue remain priority goal ensure reliable efficient supply product boehringer ingelheim invest capacity expansion strong revenue con tributor nexgard barceloneta puerto rico facility expansion small animal vaccine production company facility athens georgia usa expansion vaccine capacity lyon france st joseph missouri usa capacity expansion footandmouth disease vaccine jonage france expansion pharma ceutical manufacturing capacity toulouse france invest development modern technology manufacture product biopharmaceutical contract manufacturing boehringer ingelheim pursue biopharmaceutical activity facility biberach lead germany vienna austria fremont california usa shanghai china comprise biopharma provid manufacture ownbrand marketable product actilyse metalyse ers industrial praxbind manufacture biopharmaceutical clinical testing pipeline product customer world lead company process development launch preparation com mercial production biopharmaceutical thirdparty industrial customer pharmaceutical company innovative biotech firm client biopharmaceutical contract manufacturing business boehringer ingelheim cover entire biopharmaceutical value chain development production cell mammalian cell microorganism production process manufacture active substance finish pharmaceu tical product product launch global market supply stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report capacity utilization establish network industrialscale production facility remain high level biberach facility optimize production process suc cessfully demonstrate bioequivalence study rampedup production meet grow market demand actilyse achieve rapid increase production volume initiate transfer optimize process new largescale cell culture plant vienna way support process submission authority eu usa japan biberach launch preparatory activity boehringer ingelheim ilr monoclonal antibody spesolimab expect introduce market microbial production facility vienna site approve customer product carrier protein vac cine microbial product portfolio increase biopharmaceutical despite challenge external condition associate covid pandemic cell culture plant biberach shanghai fremont microbial production vienna continue man ufacture deliver biopharmaceutical patient worldwide incur interruption expansion cell technology capacity vienna facility complete past year local authority authorize commission compliance good manufacturing practice gmp halfway year transfer production activity currently un derway vienna facility complete microbial expansion project production recombinant vaccine view grow global importance biotechnologically produce active substance significant increase number internal development project portfolio project key strategic relevance shanghai facility focus market supply immunooncological antibody chinese customer cancer therapy expand customer product portfolio facility shanghai china file facilitys approval mar ket activity focus supply innovative medicine patient chinese multinational biopharmaceutical company customer greatly benefit fact boehringer ingelheim contract development manufacture organization able cover entire value chain single source longterm experience technical expertise preparation product launch market supply employee report boehringer ingelheim employ people average worldwide represent increase previous year average number employee region americas europe asiaaustraliaafrica aaa group management report information group commit employee identify company aim appreciate respectful work climate boehringer ingelheim major success factor drive group positive growth high level personal commitment help fulfill joint promise ensure supply vital medicine hold particularly true worldwide pan demic annual global employee survey provide relevant feedback enable continuously improve work environment boehringer ingelheim success base innovation presence country global nature value chain international nature clientele stringent greatly varying requirement national regulator demand great flexibility organiza tion convince relationship base trust mutual openness respect empathy value strong competitive diversity think spirit inclusion relationship promote capacity innovation area business addition competitive salary boehringer ingelheim offer benefit employ ees benefit include range company pension plan flexible homebase work option numerous healthrelated benefit human resources department respon sible promote wide range opportunity innovation work signifi not aspect corporate strategy help employee nurture personal strength develop individual order well prepare challenge ahead emphasize acquisition technical expertise comprehensive qualification system vocational training major importance boehringer ingelheim company provide young people career entry opportunity time retain talented wellqualifie workforce young professional times demographic change company vocational training mean pass expertise emphasize getting know enable young professional experience aspect company value achieve goal mean hybrid learning teach average young people worldwide enrol boehringer ingelheim vocational training program boehringer ingelheim german facility young people start career different scientific technical commercial field training dualstudy course selection training dualstudy course closely coordinate discipline ensure curricula training program meet need company important aim strengthen appeal boehringer ingelheim boehringer employer current future employee boehringer ingelheim ingelheim recognition employer auditor international independent recognize employer institute awards country region represent increase global award compare previous year mean boehringer ingelheim employer time global employer approximately company receive award award distinction worldwide addition germany boehringer ingelheim grant distinction argentina australia austria brazil chile china colombia ecuador hungary indonesia italy malaysia mexico netherlands new zealand philippines poland romania russia saudi arabia singapore south korea spain thailand united kingdom vietnam stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report sustainable development generation sustainable sustainability firmly anchor corporate philosophy boehringer ingelheim development found understand awareness sustainability continuously devel strategy ope generation influence decisionmake action learn global pandemic obvious imperative holistic approach address intertwine connection human animal environment focus human animal health boehringer ingelheim position provide relevant contribution healthier sustainable future update sus tainability strategy entitle sustainable development generation process focus follow definition designate impact area strong usage syn ergie unify company global collaborative network ensure alignment un sustainable development goal strategy base follow pillar health people animal potential community people green planet boehringer ingelheim aim achieve follow concrete measurable goal health expand access healthcare additional million people vulnerable community invest billion eur health innovation research tackle non communicable disease additional million eur partnership combat emerg e infectious disease potential aim positively impact million people vulnerable community empower support employee partner innovative social entrepreneur green carbonneutral company operation scope significantly reduce resource footprint value chain period despite grow business activity group management report information group health people animal health follow ambition develop well therapy enable well solution health global healthcare challenge pillar include number project initiative reflect focus diversity patient expertise partner include health people animal access healthcare access healthcare initiative seeks improve healthcare vulnerable communi tie start availability medicine access safe effective prevention care achieve milestone example expand access healthcare develop region un defeatncd partnership launch joint initiative pharmaccess reach africa program kenya mobile technology improve awareness hypertension diabete lower barrier access pathway project fund launch canada intend improve life member indigenous community project address exce sive prevalence certain noncommunicable disease community pilot program launch pakistan collaboration world organi zation animal health support elimination rabie donate animal vaccine rabisin dog identification collar angel angel initiative establish improve stroke care worldwide ad ditionally clinic country doctor nurse join contin uously grow network include healthcare professional clinic country help ensure patient treat line define standard ngel initiative feature access medicine report good practice example capacity building distinguish world stroke organization stroke service award lastmile south sahara smallholder farmers africa lack access veterinary treatment joint initiative lastmile aim achieve longterm sustain improvement availability veterinary product service project launch kenya expand cameroon nigeria mali burkina faso ethiopia currently lastmile live stock service provider llsp work field relevant veterinary medicine farm management module add llsp training program new prod uct include product portfolio subsequently total product include total lastmile assist farmer provide numerous animal trader visit veterinarian visit stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report potential community people potential potential focus provide safe good possible condition focus people order people boehringer ingelheim community partner reach community potential safe safe program establish place particular emphasis ensure safe workplace employee partner continuously review optimize work safety culture strive maintain employee longterm good health preventing accident incident occupational health risk boehringer ingelheim official partner euosha healthy workplace lighten load campaign prevent workrelate musculoskeletal disorder msds addition spring internal campaign shed light launch raise awareness mental health issue workplace encourage employee speak address diversity inclusion core value empathy respect passion trust foster diverse collabo rative open inclusive work environment key innovation value creation sustainable growth boehringer ingelheim convince value diversity right thing people community smart thing business help understand fulfill different need requirement patient customer partner globe continue focus awareness education include update training program topic unconscious bias inclusive behavior human right boehringer ingelheim continuously step effort area human right ethic approach align united nations guide principle business human right subsequently human right policy integral component guide line cooperation external partner eg code conduct make health boehringer ingelheim ashoka world large network social entrepreneur jointly establish make health mmh initiative longterm partnership fo cuse enable innovative solution tackle complex healthcare challenge people animal community approach link interdependent issue economic development infrastructure education culture healthcare issue emphasize collabora tion community equal partner engage boehringer ingelheim employee share knowledge skill highlight include social innovation date innovator worldwide working area human animal health support community activation program initiate india kenya nigeria ghana impact life prove game changer include clean water hygiene project implement innovative farming model provide animal health business skill train course inclusion program marginalize community group people albinism group management report information group crosssector collaboration make health emphasize winwin collaborative approach bridge gap business society initiative busi ness accelerator funding program initiative provide funding expertise support social startup subsaharan africa enabling scale sustain business model social enterprise progress stage sub stantial funding necessary subsequently new initiative boehringer ingelheim social engagement launch investment million eur offer addition corporate donation alterna tive financing opportunity social entrepreneur include example provision subordinate loan term condition adjust local need requirement social enterprise mmh connect platform launch aim enable match boehringer ingelheim employee support effective innovative partnership social enterprise able contribute skill develop ing individual make health convention twoday virtual event bring participant academia nonprofit industry political sector interactive session participant discuss resolve world press healthrelate issue green planet healthy planet prerequisite healthy people animal communitie environmental green challenge see isolation tangible effect health focus society sustainable use natural resource promotion strong environmental environment awareness subsequently key component environmental sustainability program order help protect health current future generation safeguard prospect healthy future green fund support internal project area decarbonization water management circular economy provide fund approximately new environmental project worldwide boehringer ingelheim pay particular attention ecological aspect major project set aside additional mil lion eur purpose boehringer ingelheim pharmaceutical company eu receive greencanteen certification sustainable catering concept ingelheim headquarters stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report carbon footprint continuously work reduce greenhouse gas emission commit carbonneutral operation scope renewable electricity continue substantial investment sustainable technology tool process introduction internal carbon price eur ton create additional economic incentive green innovation recent example activity include construction new biomass power plant ingelheim transition renewable electricity solution numerous location include site germany austria spain usa company share renewable elec tricity purchase worldwide increase certification carbon neutrality site dortmund sant cugat partnership climateseed support biodiversity protect drink water offset carbon emission reforestation project africa india indonesia germany resource use circular economy aspect implement stage value chain minimize waste apply ecodesign green chemistry concept new product continuous opti mization measure reduce annual volume waste landfill resource use optimize environmental footprint future boehringer ingelheim product water stewardship access clean water major impact social cultural justice environmental sus tainability local economy reason boehringer ingelheim implement program relate water relate risk production site site establish water scarcity area implement recognize water stewardship program alliance water stewardship aw aws certification promeco production facility xochimilco mexico renewed aws certification process production facility fremont california usa initiate furthermore evaluate wastewater production site possible residue active pharmaceutical ingredient api trace substance basis clean water initiative ensure trace pharmaceuticals wastewater remain signifi cantly effect level initiative work industrial network supplier cover entire value chain context boehringer ingelheim finance joint project make health kenya aim improve access clean water group management report report economic position report economic position macroeconomic environment world economic output recover follow covidrelated collapse accord international monetary fund imf global economy grow month year economy experience upswe ease measure introduce order contain pandemic account increase level consumer demand growth slow second half year factor include industrial enterprise continue global supply capacity bottleneck rise commodity price freight cost trade policy situation usa china remain tense increase tension reflect ed factor increase import duty conflict russia ukraine closely monitor sign rise inflation unlike sector pharmaceutical market tend shape longterm economic output grow human particular society demographic trend performance influence pharma market continuous global improvement access healthcare global pharmaceutical market allow increase include covid vaccine increase trillion usd past year corre investment rd spond average annual rate growth past year source iqvia develop country growth contribution decrease relative situation start decade pharmaceutical industry social distancing measure result delay clinical study impact schedule research activity compensat ed additional cost possible largely stable core business comparison industry allow pharmaceutical company remain key driver investment research development include fight sarscov virus healthcare system globe pressure covid pandem ic burden chronic disease age population increase budget pressure order address challenge government healthcare authority expand use costcontainment action include mandatory price reduction external reference pricing lengthy complex negotiation process delay access innovative new med icine patient increasingly involved cost treatment different form copayment measure increasingly put pressure pharmaceutical com panie limit future ability invest development new treatment option improve access innovative medicine pharmaceutical industry work government healthcare authority address challenge maintain improve sustainable patient access reduce access delay continuously bring innovation patient important prerequisite achieve objective remain reliable legal framework promote innovation ensure protection intellectual property animal health market consist pet livestock segment continue pos animal health itive growth trend mainly reflect population growth people rise living market continue standard emerge market animal improve life expectancy continuous positive growth advance veterinary care pet segment pet grow popularity covid trend pandemic prompt increase level demand product livestock segment bene fit grow demand animal product increase prevalence zoonosis infec tious disease transmissible animal human human animal stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report reinforce importance animal health industry general consolidation merger supplier customer side ongoing result increase com petition future growth animal health business largely drive therapeutic innovation order grow market investment need continuous sustainable competitive accord imf global economy grow advanced economy broad access covid vaccine expect pandem icrelate decline economic output end different scenario regard inflation trend inflation return prepandemic level accord imf large number risk associate world economic growth vaccineresistant mutation covid pathogen uneven access vaccine result increase gap develop country emerge market advanced economy addition ongoing climate change increase risk natural disaster related health economic impact currency trend boehringer ingelheim global presence mean currency trend influence revenue fig ure dollar usd japanese yen jpy chinese renminbi cny particu larly worthy note follow low eurusd january start year dollar reach high eurusd december end year japanese yen fluctuate high eurjpy january low eurjpy june start year chinese renminbi low eurcny january reach high eurcny end year december significant transactional currency risk hedge suitable currency instrument currency development effect net sale average rate basis eur million eur dollar japanese yen chinese renminbi earning position stable competitive earning position solid financing guarantee boehringer ingelheim independence central activity basis pursue guide principle value innovation contribute improvement human animal health mean innovative therapy group management report report economic position boehringer ingelheim positive growth trend remain intact record net sale million eur represent increase relative previous year net sale figure million eur exchange rate effect adversely affect sale trend adjust effect group achieve growth rate billion eur net sale achieve sale growth region previous year sale million eur growth share overall sale america region boehringer ingelheim key sale region market grew currencyadjuste europe region register strong e level sale growth past financial year rate currencyadjuste sale volume amount million eur represent share group sale positive trend mainly drive global licensing business allocate region market germany spain united kingdom country eastern europe asiaaustraliaafrica aaa region sale increase currencyadjuste million eur especially institutional price adjustment core market degree continue effect covid pandemic course business aaa region unable emulate growth rate register previous year net sale region million eur currency change adjust americas europe asiaaustraliaafrica aaa human pharma business product available pa tient thank new approval additional country strengthen establish product include product jardiance family ofev especially global licensing business provide significant growth contribution rd pipeline devel oping positively important milestone reach animal health business grow particularly pet segment biopharmaceutical contract manufacturing business commission largescale cell culture plant vienna key milestone highlight financial year key figure million eur change net sale operating income return net sale income taxis income taxis stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report material ratio take consideration change inventory rise slightly personnel expense increase primarily additional employee hire area research development medicine biopharmaceutical me icine production strategic significance boehringer ingelheim amortization intangible asset depreciation tangible asset mil lion eur lower compare previous year particularly attributable high vol ume impairment loss intangible asset financial year hand continue high level investment activity acquisition result increase amortization intangible asset depreciation tangible asset achieve growth business financial year operating come increase million eur positive sale trend business enable longterm investment research development increase research development expenditure percentage net sale financial year return sale fall high price procurement market increase number employee strategically important area invest ment financial income hold income influence oneoff effect previous year hold income include profit sale investment low reason especially financial income improve particular new method introduce measurement longterm obligation income taxis rise particularly high operating income income taxis likewise higher previous year reflect improve pretax profit low income taxis note regard pro vision german commercial law shareholder personal taxis arise group business activity recognize tax expense instead taxis present withdrawal group equity take specificity account actual tax ratio markedly high figure show profit loss statement despite challenge market condition business area heighten cost pre sure boehringer ingelheim register positive performance financial year fol billion eur lowing group profit million eur previous year figure rise group profit million eur million eur group management report report economic position development business past year boehringer ingelheim activity divide human pharma animal health biopharmaceutical contract manufacturing business net sale business million eur currency change adjust human pharma animal health biopharmaceutical contract manufacturing sale discontinue operation human pharma human pharma business mainstay boehringer ingelheim activity account share group net sale sale human pharma business increase currencyadjuste financial year million eur growth mainly drive establish product jardiance family ofev grow volume license business particular skyrizi license abbvie responsible marketing product key contribution positive development human pharma business human pharma net sale product million eur currency change adjusted jardiance family ofev trajenta jentadueto spiriva pradaxa strong revenue contributor jardiance treat type jardiance diabete jardiance family generate net sale million eur ofev drive growth currencyadjuste higher previous year ofev boehringer ingelheim second biggestselling product mainly treat idiopathic pulmonary fibrosis additional indication sscild pfild ofev record net sale million eur achieve growth rate currency adjust unlike previous year trajenta jentadueto treat type diabete return sale growth sale increase currencyadjuste million eur stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report spiriva treatment chronic obstructive pulmonary disease copd register decline sale figure reflect stage product reach life cycle line expectation net sale volume million eur currencyadjuste lower previous year sale anticoagulant pradaxa fall currencyadjuste yearover year sale volume million eur pradaxa remain boehringer ingelheim biggestselling medicine financial year sale growth currencyadjuste likewise register licensing income provide skyrizi product market globally partner abbvie base risankizumab medication treatment plaque psoriasis mainly devel oped boehringer ingelheim medicine approve market treatment crohns disease psoriasis arthritis sale volume financial year reflect relate oneoff milestone payment human pharma business achieve growth region yearoveryear term regional distribution revenue usa remain strong revenue contributor growth rate currencyadjuste million eur represents share human pharma businesss overall sale volume achieve net sale million eur eucan region europe canada australia new zealand growth rate currencyadjuste eucan region gain importance share sale point higher previous year company emerge market register improved volume sale past finan cial year growth rate currencyadjuste overall sale coun try rise million eur singledigit growth emerge market fall short expectation chinese market particularly challenging sale fall currencyadjuste inclusion core product country national reim bursement drug list use volumebased procurement mechanism japan account total net sale human pharma business sale rise currencyadjuste million eur human pharma net sale region million eur currency change adjust usa eucan emerge market japan animal health past financial year animal health business achieve net sale total mil lion eur provide group sale animal health increase sale volume currencyadjuste step pace growth relative previous year growth drive pet segment group management report report economic position animal health net sale product million eur currency change adjust nexgard frontline heartgard ingelvac circoflex flexcombo segment account biggestselling medicine animal health business pet segment tiparasitic nexgard frontline register growth rate currencyadjuste drive growth currencyadjuste past year nexgard achieve sale volume million eur remain biggestselling product animal health portfolio frontline secondbigg seller revenue million eur medicine heartgard suffer decline currencyadjuste sale past financial year product prevent heartworm disease contribute mil lion eur animal health business sale volume swine vaccine ingelvac circoflex register decline sale volume revenue fall currencyadjuste million eur continue challenge associate african swine fever key market animal health business surpass previous year sale volume region usa achieve currencyadjuste growth register positive course business financial year particularly pet segment include horse compensate slightly low sale figure swine segment eucan region likewise register strong sale growth pet segment hand growth swine poultry segment fail match expectation overall sale growth eucan region amount currencyadjuste tcm region chinese market improve sale volume currencyadjuste yearoveryear growth mainly drive swine segment alamea asia latin america middle east africa region register sale growth currencyadjuste sale pet segment high livestock segment animal health net sale region million eur currency change adjust usa eucan alamea tcm stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report biopharmaceutical contract manufacturing continue strong biopharmaceutical contract manufacturing business revenue currency growth adjust high previous year strong demand business biopharmaceutical partner market product order situation entire business develop positively contract result high level capacity utilization manufacturing salesdiscontinue operation discontinue operation aggregate activity minor strategic importance boehringer ingelheim net sale decrease expect financial position boehringer ingelheim financial management strategy aim safeguard company financ ing mean operate cash flow far possible minimize financial risk optimize cost capital cash inflow operating activity amount million eur attributable positive business performance financial year million eur lower previous year million eur mainly increase receivable high tax payment million eur financial fund cash flow operating activity cash flow investing activity cash flow financing activity change financial fund cash relevant transaction change financial fund exchange rate movement valuation adjustment financial fund cash outflow investment activity increase significantly million eur million eur financial year cash holding fund previously invest current asset invest longterm security addition previous year include oneoff payment share business divestiture high capital milestone achieve context large investment tangible asset expenditure volume expansion production facility vienna austria biopharmaceutical enable business contract manufacturing successfully complete million eur development invest vienna site germany construction biological development center bdc expansion research site biberach promote year investment amount million eur supplement number high investment boehringer ingelheim global research development network group management report report economic position animal health boehringer ingelheim invest new antigen production center jonage france veterinary public health response grow demand medicine treat footandmouth bluetongue disease total investment project mil lion eur approximately million eur pay past financial year cash outflow financing activity million eur mainly comp rise tax refund shareholder personal taxis associate group activity amount report group tax expense commercial law regulation overall take consideration change exchange rate movement valua tionrelate change group financial fund decrease total million eur million eur december particular transfer cash short term security longterm financial asset net asset position million eur change change asset intangible tangible asset financial asset fix asset inventory trade account receivable receivables current asset security cash cash equivalent current asset asset total asset equity liability group equity provision pension similar obligation tax provision provision account payable loan thereof residual term year liability liabilitie difference capital consolidation total equity liability december boehringer ingelheim total asset amount million eur increase million eur compare previous year increase mainly attributable investment tangible asset acquisition positive cash flow financial year inventory receivables rise positive currency effect increase balance sheet item intangible tangible fix asset increase acquisition continuously high volume capital expenditure strategic expansion company business include stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report human pharma research germany biopharmaceutical vienna austria fremont california usa animal health france addition positive currency effect crease volume fix asset fund previously hold cash invest shortterm investment invest longterm security investment fund result cash flow course financial year longterm secu rities investment significantly increase volume longterm financial asset work capital inventory receivables rise increase production cost result high price level procurement market buildup safety stock bio pharmaceutical contract manufacturing animal health positive currency effect trade account receivable rose usa reporting date increase volume receivables wholesaler germany increase volume receivables arise license agreement rise receivables asset sulte increase tax prepayment sale tax receivables germany mexico usa particular asset increase higher defer tax asset result tem porary difference valuation consolidate company tax balance sheet valuation consolidate balance sheet pension provision especially positive market trend plan asset pension similar obligation item increase currency effect equity amount million eur december equity ratio improve december spite high balance sheet total addition billion eur equity pension provision longterm liability available group capital equity long term item total million eur december repre senting share total asset consequently previous year longterm disposable capital continue cover intangible tangible fix asset work capital equity ratio pension provision rise germany particular decline discount rate currency effect increase provision correlate change level revenue include provision discount usa commission royalty payment addition positive currency effect result high tax provision provision volume liability rise increase debt financing brazil greece china advance payment customer biopharmaceutical contract man ufacture business liability shareholder positive currency effect liability decline mainly release difference arise capital consolidation defer income net asset position likewise reflect boehringer ingelheim positive development financial year boehringer ingelheim remain soundly finance company make con siderable capital expenditure development business research activity order ensure longterm growth independence group management report report opportunitie risk report opportunity risk opportunitie risk management assess risk context holistic opportunity risk management endeavor account result opportunity opportunity management base strategy objective company indi vidual business operate business unit integral groupwide plan ne management system responsible business function bear direct responsibility early systematic identification analysis use opportunity boehringer ingelheim researchdriven biopharmaceutical company current research development activity naturally consider opportunity relevant project al ready outline research development chapter consider digitalization opportunity new technological possibility area research particu larly clinical development support patient therapy current covid pandemic give great priority opportunity digitalization different area especially sale administration aim risk management system implement boehringer ingelheim identi fy businessspecific risk early possible particularly risk jeopardize continued existence company assess reduce reasonable level mean suitable measure person responsible key business function include process calculate assess risk groupwide risk information system ensure identify risk analyze assess carefully follow appropri eat classification adequate risk management measure initiate implementation consistently monitor year review internal auditing perform target routine audits extraordi nary audits world addition adherence legal requirement internal group guideline main focal point functionality system effectiveness internal control prevention loss asset efficiency structure process correspond adjustment optimization initiate necessary individual risk key risk boehringer ingelheim expose broken follow specific category financial risk legal risk information technology risk production environmental risk personnel risk sectorspecific risk risk identify concrete appear controllable mean specific management procedure term abstract case risk completely control mean target management procedure regardless probability occurrence stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report financial risk relevant financial risk break follow currency risk geopolitical risk credit country specific risk financial investment shareholding risk currency risk global orientation business activity subject risk opportunity ex change rate volatility relation dollar japanese yen regard emerge market currency especially chinese renminbi group monitor quantifie risk regular interval make predictable future business mean relevant hedging strategy appropriate financial instrument forward exchange contract resultant risk subsequently designate concrete con trollable limited geopolitical risk business boehringer ingelheim global company adversely affect geo political development significant risk arise example geopolitical tension change economic political condition impact production site sale market global geopolitical development constant observation boehringer ingelheim order able appropriate measure early stage address abstract low risk maintain successful global business credit country specific risk boehringer ingelheim expose credit countryspecific risk result international business activity portfolio trade account receivable trade ac count payable identify extraordinary risk group usual level industry start covid pandemic compare previous year apply possible default risk receivables largely hedge economic political risk continue carefully track credit countryspecific risk position respond negative change timely manner risk consider moderate regard concrete financial investment shareholding risk group pursue conservative investment strategy management financial asset primary objective longterm preservation real value reflect orientation portfolio mainly comprise money market bond investment result concrete controllable limited level risk financial investment net book value strategic investment relate company affect market business circumstance lead high level volatility fair market value specific risk cover respective impairment consolidate finan cial statement group management report report opportunitie risk legal risk business activity group expose legal risk distinction regulatory liability patent protection risk regulatory risk boehringer ingelheim expose risk arise legal dispute proceeding official investigation legal administrative decision ongoing future proceeding predict regard resultant risk abstract high liability risk marketing sale pharmaceutical expose potential product liability risk boehringer ingelheim currently product liability insurance company risk profile absolutely guarantee insurance coverage maintain reasonable cost acceptable condition sufficient protect boehringer ingelheim claim loss potential claim loss case foreseeable product liability insurance cover partially cover specific liability risk remain risk exposure cover provision moderate risk group furthermore product liability claim tie substantial financial resource manage ment capacity detrimental company image event market consider product unsafe ineffective result unexpected effect abstract moderate risk patent protection risk protection innovation trademark patent right particular importance boehringer ingelheim researchdriven biopharmaceutical company commercial pro tective right increasingly target attack breach take necessary precaution allow detect threat early stage commence appropriate countermeasure defend legal position legal mean available factor regard concrete moderate risk information technology risk boehringer ingelheim use globally network system core area operation busi ness production process internal external communication make use cloudbase thirdparty system service system process store transmit confidential personal datum availability integrity confidentiality system datum process highly significant stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report external cyberattack manipulation system result loss information expertise temporary interruption business production process risk consider high concrete view continuously evolve global environment grow frequency cyberattack covid pandemic elevate risk threat attack people creasingly work home employee access sensitive datum secure environment boehringer ingelheim counter risk mean continuous process analysis improvement preventive reactive measure helps identify ward current threat minimize potential damage production environmental risk quality management system compliance process continuously optimize close cooperation relevant authority order ensure compliance cgmp standard current good manufacturing practice risk area continue high significance group classify abstract boehringer ingelheim implement riskmitigate measure past year order counter covidspecific threat production activ itie include physical segregation production team possible obligation wear mask increase supply disinfectant inhouse initiative test covid status employee order protect facilitybased function employee presence sitedependent ask work home order ensure supply product market implement measure guarantee reliable highquality supply internal external customer addi tion supplier management procurement involve build internal standby capacity overall represent concrete moderate risk risk area environment health safety sustainability ehss preemptive ly minimize ensure global adherence high safety standard appropriate emergency plan draw possible incident kind practice subject comprehensive quality testing regular interval result measure risk class concrete limited personnel risk boehringer ingelheim company expose demographic change resultant risk affect lack appropriately qualified personnel potential risk substantial impact company business activity include longterm planning process year gain strategic significance result group management report report opportunitie risk boehringer ingelheim counter risk mean comprehensive personnel concept context global personnel management present group opportunity gardless ethnic background gender religion offer company employee development opportunity base professional ability social skill personal aptitude willingness responsibility accordance need company view measure describe risk regard concrete moderate boehringer ingelheim likewise expose human resource risk result covid pandemic pathogen spread significant impact outside production activity company closely monitor situation vicinity site emphasize work home digital application inperson meeting curb employee travel large extent view measure consider concrete moderate risk industryspecific risk boehringer ingelheim subject industryspecific business risk pharmaceutical industry risk partly materialize past financial year creasingly important boehringer ingelheim effect continue class abstract high addition loss exclusivity product establish market risk associate development registration new medicine risk creasingly include change restrictive requirement relate pricing reimbursement sale market frequently price pharmaceutical product subject state monitoring regulation price pressure cheap generic drug induce state reimbursement system boehringer ingelheim keep close eye change sale market take appropriate measure response current development overall statement risk situation current perspective aware risk conjunction risk lead lasting impairment company asset financial earning posi tion jeopardize continued existence boehringer ingelheim stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report report expect development boehringer ingelheim look successful financial year surpass ambitious target term absolute figure contribution wellbee patient pet livestock despite volatile global economic situation able ensure company sustainable development profitable growth continue covid pandemic fragile global supply chain general inflation trend difficult industry environment mean continue face challenge uncertainty past year context global pandemic ap pear gradually give way predictable challenge opportunity optimistic view ongoing volatility remain difficult forecast come financial year expect ongoing global economic recovery assume vaccine medicine approve plus therapy currently undergo approval pro cess help curb covid pandemic strength experience past year measure implement confident able handle temporary setback encounter substantial supply problem large source uncertainty year potential impact economic factor government budget planning affect policymake term expenditure healthcare medicine assume possible curb c ovid pandemic expect moderate market growth prescription pharmaceutical witness grow global institutional effort bring price medicine view trend financial flexibility remain critical order ensure longterm growth innovation animal health business follow strong market growth expect normalization market growth trend new financial year research innovation play particularly important role business partner intend continue provide customer innovative solution development african swine fever situation remain critical factor priority biopharmaceu tical business supply market product contract manufacturing business partner increase level capacity utilization new largescale cell culture plant vienna core area focus expect boehringer ingelheim achieve slight yearonyear increase net sale comparable basis adjust currency extraordinary effect consistently high rd expenditure increase line strategic focus continue drive growth flow new product achieve goal obtain rd external innovation nership continue actively pursue strategy invest external rd close investigation therapeutic benefit associate prospect success flow innovative medicine research development pipeline show short medium longterm growth potential expect increase rd investment new medicine intend reach new milestone research development individual market approval group management report report expect development addition patent expiry attack patent major challenge face researchdriven pharmaceutical industry increase investment rd big hurdle increase cost associate product approval particular note previously mention grow cost pressure healthcare system year pandemic researchdriven pharmaceutical company display unprecedented level network energy develop solution extremely quickly prove societal value research innovation support policymaker additional concrete step need contribution pharmaceutical company increase efficiency overall healthcare system remunerate appropriately animal health research likewise require major investment preventive research diagnostic option conjunction long planning development cycle new product grow public cost pressure mean business predictable require quickly recognize seize opportunity human pharma animal health hand contin uously monitor adjust cost strategy implement measure business area accelerate speed response change reduce complexity organization optimize cost base way create potential capital expenditure securing company longterm success expect boehringer ingelheim achieve slightly low operating income increase level investment research development comparable basis adjust currency extraordinary effect familyowne company boehringer ingelheim primary aim remain creation value innovation safeguard competitiveness longterm entrepreneurial independence confident achieve ambitious target business area thank great innovative strength rest comprehensive portfolio pro spective product global presence support highly qualified motivated employee remain committed ambition company research develop innovative product human veterinary medicine bring market area high medical need break new ground therapeutic approach aim endeavor new medicine available human animal treat effectively new therapy stnemetat laicnanif detadilosnoc oiloftrop tcudorpneuronal cell connection human brainconsolidate financial statement verview select consolidated company consolidate balance sheet consolidate profit loss statement consolidate cash flow statement statement change group equity n ote consolidated financial statement independent auditor report stnemetat laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report overview select consolidated company ch boehringer sohn ag co kg ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina italy p taiwan germany p r boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina sa buenos aire italia spa milan taiwan co ltd taipei center gmbh ingelheim rhein australia japan r thailand boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd north ryde japan co ltd tokyo thailand limited bangkok gmbh co kg ingelheim rhein boehringer ingelheim microparts belgium p r mexico p usa p r gmbh dortmund boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim venture fund belgium sa brussels mxico sa de cv mexico city usa inc wilmington delaware gmbh ingelheim rhein boehringer ingelheim veterinary boehringer ingelheim medicine belgium evergem netherlands r vietnam biopharmaceutical gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim vietnam ltd brazil p netherlands bv alkmaar ho chi minh city boehringer ingelheim middle east africa gmbh boehringer ingelheim animal health ingelheim rhein brasil ltda paulo new zealand p boehringer ingelheim animal health canada new zealand limited auckland boehringer ingelheim animal health canada inc burlington philippines boehringer ingelheim animal health china p r philippines inc makati city nanchang boehringer ingelheim animal health co ltd nanchang puerto rico p boehringer ingelheim animal boehringer ingelheim animal health health shanghai co ltd puerto rico llc barceloneta shanghai boehringer ingelheim animal south africa health operation china co ltd taizhou boehringer ingelheim animal health boehringer ingelheim vetmedica south africa pty ltd midrand china co ltd taizhou gauteng denmark p south korea boehringer ingelheim animal health boehringer ingelheim animal health denmark copenhagen korea ltd seoul france p r spain boehringer ingelheim animal health boehringer ingelheim animal health france lyon espaa sa barcelona great britain p boehringer ingelheim animal health uk limit bracknell distribution p production r research development consolidate financial statement overview select consolidated company ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina denmark japan p r serbia boehringer ingelheim sa boehringer ingelheim danmark nippon boehringer ingelheim co boehringer ingelheim serbia doo buenos aires copenhagen ltd tokyo beograd belgrade boehringer ingelheim seiyaku australia ecuador yamagata south africa boehringer ingelheim pty ltd boehringer ingelheim del ecuador ingelheim pharmaceutical north ryde cia ltda quito mexico p proprietary ltd midrand gauteng boehringer ingelheim mexico sa de austria p r finland cv mexico city south korea boehringer ingelheim rcv boehringer ingelheim finland ky boehringer ingelheim vetmedica sa boehringer ingelheim korea ltd gmbh co kg vienna espoo de cv guadalajara seoul boehringer ingelheim promeco sa forschungsinstitut fr molekulare de cv mexico city pathologie gesellschaft mbh vienna france spain p viratherapeutic gmbh rum boehringer ingelheim france sas netherlands boehringer ingelheim espaa sa paris barcelona belgium boehringer ingelheim bv alkmaar scs boehringer ingelheim commv germany r sweden brussels boehringer ingelheim new zealand boehringer ingelheim aktiebolag therapeutics gmbh ochsenhausen boehringer ingelheim nz ltd stockholm brazil p auckland boehringer ingelheim brasl great britain switzerland r qumica e farmaceutica ltda boehringer ingelheim ltd norway boehringer ingelheim schweiz paulo bracknell boehringer ingelheim norway ks gmbh basel asker nbetherapeutics ag basel canada greece p amal therapeutic sa geneva peru boehringer ingelheim canada ltd boehringer ingelheim ellas single toronto member sa athens boehringer ingelheim peru sac taiwan lima boehringer ingelheim taiwan ltd chile hong kong taipei philippines boehringer ingelheim ltda boehringer ingelheim hong kong santiago de chile ltd hong kong boehringer ingelheim philippines thailand inc manila boehringer ingelheim thai ltd china p india bangkok poland boehringer ingelheim shanghai boehringer ingelheim india private pharmaceuticals co ltd shanghai ltd mumbai boehringer ingelheim sp z oo turkey boehringer ingelheim warsaw boehringer ingelheim ila ticaret biopharmaceutical china co ltd indonesia p istanbul shanghai portugal pt boehringer ingelheim indonesia boehringer ingelheim china jakarta boehringer ingelheim portugal lda usa p r investment co ltd shanghai lisbon bi x ehealth technology shanghai boehringer ingelheim co ltd shanghai isr ba oe el hringer ingelheim israel ltd russia p wh ila mrm ina gc te ou not dca el ls w ac colombia tel aviv ooo boehringer ingelheim moscow boehringer ingelheim fremont inc wilmington delaware boehringer ingelheim sa italy p saudi arabia boehringer ingelheim usa santa f de bogot corporation wilmington delaware boehringer ingelheim italia spa boehringer ingelheim saudi arabia czech republic milan trading riyadh vietnam bidachem spa fornovo giovanni boehringer ingelheim spol sro boehringer ingelheim animal health prague vietnam limited liability company ho chi minh city oiloftrop tcudorp boehringer ingelheim annual report consolidate balance sheet asset million eur note intangible asset tangible asset financial asset fix asset inventory account receivable asset security cash cash equivalent current asset prepaid expense defer tax asset exceed plan asset total asset equity liability million eur note shareholder capital group reserve balance sheet currency conversion difference equity attributable parent company noncontrolle interest group equity difference capital consolidation provision account payable loan liability defer income defer tax liabillitie total equity liability explanation relevant section note consolidated financial statement consolidate financial statement consolidate balance sheet consolidate profit loss statement consolidated profit loss statement million eur note net sale change finish good work process work capitalize operating income total revenue cost material personnel expense amortization intangible asset depreciation tangible asset operating expense operate income financial income hold income income taxis income taxis income taxis net income noncontrolle interest group profit explanation relevant section note consolidated financial statement legal requirement shareholder personal taxis arise group business activity show withdrawal group reserve oiloftrop tcudorp boehringer ingelheim annual report consolidate cash flow statement million eur income taxis include noncontrolle interest amortization depreciation writedown reversal writedown intangible tangible financial asset change provision pension similar obligation include change plan asset change provision noncash income expense gain disposal consolidate company gain loss disposal fix asset grant receive change inventory change account receivable asset relate investing financing activity change account payable liability relate investing financing activity interest income interest expense income investment income expense income taxis income taxis pay cash flow operating activity payment acquire intangible fix asset payment acquire tangible fix asset payment acquire financial fix asset payment acquire plan asset payment relate purchase price adjustment consolidate entity investment consolidated company proceed disposal intangible fix asset proceed disposal tangible fix asset proceed disposal financial fix asset proceed disposal consolidated entity interest receive income dividend cash flow investing activity consolidate financial statement consolidated cash flow statement statement change group equity consolidated cash flow statement continue million eur cash receipt grant interest pay cash receipt shareholder parent company cash payment shareholder parent company proceed loan cash repayment loan cash flow financing activity change financial fund cash relevant transaction change financial fund exchange rate movement valuation adjustment financial fund financial fund line mainly contain shareholder personal taxis arise group business activity accord legal requirement include group tax expense cash cash equivalent security current asset source fund use fund statement change group equity balance sheet equity currency attributable non shareholder group conversion parent control million eur capital reserve difference company interest group equity balance withdrawal net income currency effect balance withdrawal net income reduction recognition defer tax liability recognize directly equity change consolidate company currency effect balance shareholder capital consist equity ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consist limited partner capital contribution shareholder personal taxis arise group business activity show withdrawal group reserve oiloftrop tcudorp boehringer ingelheim annual report note consolidated f inancial statement principle method general principle consolidate financial statement boehringer ingelheim financial year prepare accordance section german commercial code hgb line legal requirement prepare consolidated financial statement section et seq hgb accordance section hgb consolidated financial statement consist consolidated balance sheet consolidated profit loss statement note consolidated financial statement consolidated cash flow statement statement change equity consolidated financial statement prepare euro accordance section conjunction section hgb improve clarity transparency consolidated financial statement subtotal add con solidate profit loss statement furthermore individual item consolidate balance sheet c onsolidate profit loss statement combine item present explain separately note additional disclosure require individual item find note registry information parent company register ch boehringer sohn ag co kg headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group ch boehringer sohn ag co kg ingelheim rhein boehringer ag ingelheim rhein sole unlimited partner company boehringer ingelheim group consist total affiliated company germany abroad sub sidiarie include consolidated financial statement ch boehringer sohn ag co kg con olidation rule ch boehringer sohn grundstcksverwaltung gmbh co kg special purpose entity ch boehringer sohn ag co kg bear majority risk opportunitie economic term ch boehringer sohn ag co kg hold majority voting right subsidiary directly indirectly consolidated financial statement note consolidated f inancial statement accordance section hgb subsidiary include consolidation reporting year individually collectively insignificant group net asset financial earning position total sale equity net income year subsidiary include consolidation account percent aggregate group financial statement total subsidiary ongoing restriction control term article association accordance section hgb company consolidate total number subsidiary increase compare previous year company acquire company lose separate legal identity merger affiliated company liquidate affiliated company sell follow subsidiary exempt report disclosure obligation section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim finanzierung gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim rhein boehringer ingelheim grundstcksgmbh ingelheim rhein boehringer ingelheim rd beteiligung gmbh ingelheim rhein boehringer ingelheim animal health france participation gmbh ingelheim rhein boehringer ingelheim finanzinvest gmbh ingelheim rhein follow subsidiary exempt report disclosure obligation section b hgb ch boehringer sohn ag co kg ingelheim rhein ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim pharma gmbh co kg ingelheim rhein boehringer ingelheim veterinary research center gmbh co kg ingelheim rhein boehringer ingelheim participate joint venture include consolidated financial state ment proportionate method equity method material furthermore boehringer ingelheim hold interest associate company account equity method lack significance result effect group total asset net income percent oiloftrop tcudorp boehringer ingelheim annual report consolidation method inventory fix asset receivables liability income expense item transaction com panie include consolidation eliminate debt consolidation procedure accordance section hgb procedure eliminate intercompany profit accordance section hgb income expense consolidation procedure accordance section hgb revaluation method apply include subsidiary consolidation time accordance section hgb company include consolidation time date com pany subsidiary book value share hold parent company offset correspond equity subsidiary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time consolidation remain positive bal ance record goodwill remain negative balance record difference capital consolidation currency translation asset liability result foreign currency transaction translate average spot exchange rate balance sheet date realization principle section conjunction section half sentence hgb historical cost principle section conjunction section sentence hgb apply item remain term year consolidated financial statement financial statement foreign subsidiary domicile state outside eurozone denominate foreign currency convert euro modify closing rate method accordance section hgb modify closing rate method asset liability item annual financial statement prepare foreign currency translate euro average spot exchange rate balance sheet date exception equity translate historical rate item include profit loss statement translate euro annual average rate result translation difference report consoli date equity reserve balance sheet currency conversion difference exchange rate group important currency change follow report year basis eur spot rate average rate dollar japanese yen chinese renminbi consolidated financial statement note consolidated f inancial statement accounting policy fix asset acquire tangible intangible asset carry cost schedule straightline amortization depreciation determine consideration technical economic circumstance base follow useful life goodwill year intangible asset year building year technical facility machine year facility operating equipment year straightline depreciation amortization consolidated financial statement additional write down record reflect impairment value asset consider permanently impaired manufacturing cost include material labor manufacturing cost appropriate portion material labor overhead depreciation fix asset extent cause production manufacturing cost include financing cost capitalize intangible asset finite useful life current financial year goodwill increase overall million eur acquisition company million eur relate acquisition nbe therapeutic sa financial asset primarily include investment security shareholder right loan carry low cost fair market value impair event reason impairment loss recognize previous financial year long applicable corresponding reversal record current asset prepay expense defer income exceeding plan asset inventory carry low cost fair market value raw material consumable supply capitalize low average acquisition price fair market value balance sheet date finish good work progress measure manufacturing cost basis individual calculation take account directly attributable cost material direct labor cost special direct cost appropriate share material production overhead cost productionrelate depreciation oiloftrop tcudorp boehringer ingelheim annual report good resale value lower acquisition cost fair market value identifiable risk inventory arise aboveaverage storage period diminish marketability low replacement cost take account record appropriate valuation adjustment inventory value lossfree deduction expect sale price reflect cost incur receivables asset recognize cost allowance specific risk general credit risk low interest noninterestbeare receivables term year discount security classify current asset solely include security recognize low cost fair market value stock market price reporting date cash cash equivalent consist cash balance bank check recognize low cost fair market value prepay expense record accordance section hgb include expense pay advance respect define period time balance sheet date defer income record accordance section hgb include proceed represent income respect define period time balance sheet date fair market value pension plan asset correspond present value pension obligation offset accord german gaap exceeding plan asset capitalize separately group reserve group reserve include retain earning consolidate subsidiary prior current year consoli dation entry affect earning difference capital consolidation difference capital consolidation report december primarily result business swap boehringer ingelheim consumer healthcare business sanofis animal health business complete january result difference capital consolidation million eur difference amor tize estimate period year remain balance difference amount million eur december difference capital consolidation primarily influence current year release million eur furthermore difference capital consolidation decrease million eur sale company newport laboratories inc income release difference arise capital consolidation include operate income release correspond amortization asset acquire company identify purchase price allocation previously recognize company balance sheet consolidate financial statement note consolidated f inancial statement provision tax provision provision include uncertain liability expect loss executory contract carry require settle obligation base reasonable prudent commercial judgment include future cost price increase provision remain maturity year discount matchedterm average market interest rate case pension provision interest rate result average market interest rate year case provision average market interest rate seven year accordance rckstellungsabzinsungsverordnung german regulation discount provision environmental protection measure case expect result permanent burden relevant pro vision calculate basis perpetual annuity take consideration cost price increase interest effect valuation method adjust year review method previously long give true fair view net asset earning position group consideration decline interest rate rise inflation rate instead average rate change consumer price index past year current cost adjust inflation basis average rate change producer price index industrial product introduction euro ultimate forward rate ufr provide european insurance occupational pension authority eiopa discount instead sevenyear average interest rate term year accordance rckstellungsabzinsungsverordnung german regulation discount provision effect valuation adjustment balance sheet profit loss statement explain note account payable account payable loan recognize settlement defer taxis calculate defer taxis arise temporary quasipermanent difference carry amount asset liability prepay expense defer income commercial balance sheet carrying amount tax purpose tax loss carryforward amount result tax benefit expense time difference reverse measure tax rate specific respective consolidated company de ferred tax balance discount difference consolidation measure accordance section hgb measure companyspecific tax rate applicable time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report offset oiloftrop tcudorp boehringer ingelheim annual report note consolidated balance sheet intangible asset acquire concession advance million eur similar right goodwill payment total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate amortization balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value consolidate financial statement note consolidated f inancial statement tangible asset advance technical facility payment land facility operate construction million eur building machine equipment progress total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value oiloftrop tcudorp boehringer ingelheim annual report financial asset investment loan investment loan affiliate affiliate relate related investment million eur company companies company company security loan total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value previous year loan item include loan shareholder consolidated financial statement note consolidated f inancial statement inventory million eur raw material supply unfinished good finish good good resale advance payment supplier account receivable asset residual term residual term million eur year year trade account receivable receivables affiliate company receivables related company asset asset item include receivables shareholder million eur previous year million eur receivable affiliate company exclusively consist receivables loan receivables related company primarily consist trade account receivable provision million eur pension provision similar obligation tax provision provision oiloftrop tcudorp boehringer ingelheim annual report provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum germany example g mortality table publish prof dr klaus heubeck adjust groupspecific death probability invalidity rate pension obligation signifi not country calculate basis follow actuarial parameter december germany usa discount rate salary increase pension increase discount rate determine reference average market rate year maturity accordance german regulation discount provision march interest rate discount significant foreign pension obligation usa determine comparable parameter line german regulation discount provision march difference calculate accordance section hgb amount million eur previous year million eur plan asset intend solely cover pension similar obligation unavailable creditor plan asset define section sentence hgb measure fair market value essentially derive stock market price offset underlie pension similar obligation fair market value plan asset balance sheet date million eur relate pension obligation similar obligation million eur tax provision tax provision include provision double taxation risk result follow implementation action plan organisation economic cooperation development oecd international initiative know action plan base erosion profit shift bep consolidated financial statement note consolidated f inancial statement provision provision mainly include provision discount guarantee personnelrelate provision provision outstanding invoice provision litigation legal claim compensation damage environmental provision refer comment impact change valuation method environmental provision note use new method result million eur reduction relate provision december relative situation december reduce operating income past financial year million eur oneoff effect financial income increase million eur account payable residual term residual term thereof million eur year year year year bank loan account payable thereof trade account payable advance payment receive account payable affiliate company account payable relate company liability thereof taxis million eur social security liability million eur previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder million eur previous year million eur present liability item account payable affiliate company include loan amount million eur previous year million eur trade account payable amounting million eur previous year million eur oiloftrop tcudorp boehringer ingelheim annual report n ote consolidated profit loss statement structure consolidated profit loss statement base total cost format taxis include operating expense net sale business million eur human pharma animal health biopharmaceutical contract manufacturing sale discontinue operation region million eur americas europe asia australia africa aaa operating income operating income include income currency translation million eur previous year million eur cost material million eur cost raw material supply good resale expenditure service consolidate financial statement note consolidated f inancial statement personnel expense million eur wage salarie social benefit retirement benefit thereof retirement benefit interest effect measurement provision pension similar obligation show financial income average headcount production marketing sale research development administration apprentice amortization intangible asset depreciation tangible asset amortization intangible asset depreciation tangible asset include impairment loss million eur previous year million eur operating expense operating expense include expense currency translation million eur previous year mil lion eur addition item include operating expense mainly charge record provision thirdparty service research development medicine marketing purpose administrative expense fee contribution commission rent freight expense repair carry party legal risk restructure oiloftrop tcudorp boehringer ingelheim annual report financial income million eur interest expense similar expense amortization loss disposal financial fix asset shortterm investment income investment security longterm loan interest income similar income interest expense similar expense item include interest result provision pension similar obligation provision million eur previous year million eur interest expense similar expense million eur previous year million eur gain loss plan asset interest expense relate pension similar obligation offset accor dance section sentence hgb total million eur earning plan asset million eur interest expense relate pension similar obligation include interest expense similar expense hold income million eur writedown financial asset writeup financial asset income relate company thereof disposal relate company income taxis million eur current income taxis defer taxis current income taxis primarily include corporation trade tax expense consolidated company consolidate financial statement note consolidated f inancial statement total balance defer tax asset balance sheet date amount million eur previous year million eur defer tax asset primarily arise difference carry amount provision pension obligation discount tax goodwill intangible asset inventory tangible asset defer tax lia bilitie million eur previous year million eur recorded primarily relate difference carry amount intangible asset tangible asset inventory provision net income net income positively influence nonperiod income primarily reversal provision million eur previous year million eur negatively influence nonperiod expense particular additional expense relate provision million eur previous year million eur note consolidated cash flow statement consolidate cash flow statement show change financial fund boehringer ingelheim group result cash inflow outflow report year financial fund contain cash cash equivalent secu ritie convert cash shortterm change balance sheet item affiliate company include translate average rate year balance sheet financial fund carry spot rate effect exchange rate change financial fund show separately financial fund december comprise follow item million eur cash cash equivalent security financial fund include million eur restrict fund balance sheet date oiloftrop tcudorp boehringer ingelheim annual report disclosure contingent liability million eur liability guarantee warranty grant security thirdparty liability risk utilization contingent liability assess low account good net asset financial earning position financial commitment offbalance sheet transaction million eur rental lease obligation residual financial commitment rental lease obligation million eur previous year million eur relate longterm rental agree ment subsidiary include consolidation purpose lease agreement low capital commitment compare buy property absence resale risk risk arise term lease possible continue utilize property fully indication time residual financial commitment include investment future effect cash flow million eur previous year million eur derivative financial instrument valuation unit extensive international structure boehringer ingelheim group highly dependent development world currency interest rate hedge risk particularly emerge delivery good service finance currency forwards option generally currency risk interest rate swap option interest rate risk use derivative financial instrument organizational process set internal guideline strict separation trading processing documentation control consolidated financial statement note consolidated f inancial statement risk position regularly track analyzed measure special groupwide financial report position en tere periodically reevaluate monitor fair value derivative financial instrument calculate generally accept market valuation method currency forward base present value method take account market datum balance sheet date provision million eur recognize currency forward include hedge accounting negative fair value currency balance sheet date line imparity principle positive fair value currency recognize balance sheet date derivative financial instrument include hedge accounting valuation unit follow nominal value fair value million eur foreign exchange forward contract extent requirement hedge account foreign currency forward exchange contract highly probable forecast transaction accordance section hgb meet foreign currency forward exchange contract recognize balance sheet line net hedge presentation method follow accounting policy apply recognition valuation unit accordance section hgb economic hedge account financial statement use valuation unit valuation unit recognize foreign currency base net highly probable forecast transaction currency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale purchase derive company plan expost analysis planning show plan transaction highly probable oppose change value hedge item hedge instrument fully offset critical term turity nominal foreign currency match effective hedge assume prospectively retrospectively critical term match method exclusively measure prospective retrospective effectiveness hedge excess amount hedging transaction include valuation unit oiloftrop tcudorp boehringer ingelheim annual report december hedge highly probable forecast net cash flow recognize follow january december net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december usd january jpy net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy january net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd consolidated financial statement note consolidated f inancial statement furthermore december valuation unit foreign currency receivable recognize follow receivables million eur foreign exchange forward contract million eur nominal value nominal value fair value rub rub rub december valuation unit foreign currency receivables result loan recognize follow receivables million eur foreign exchange forward contract million eur nominal value nominal value fair value cad cad cad chf chf chf cny cny cny mxn mxn mxn rub rub rub thb thb thb usd usd usd hedge foreign currency risk correlate relative change exchange rate plan ne date realization date forecast transaction currency appreciate depreciate euro foreign currency risk million eur hedge oiloftrop tcudorp boehringer ingelheim annual report research development expense million eur research development expense noncapitalized research development expense include item cost associate clinical study total auditor fee total fee charge group auditor financial year amount million eur million eur relate audits financial statement million eur assurance service million eur tax advisory service million eur service subsequent event end financial year aware event material significance group lead reappraisal net asset financial earning position shareholding list company include consolidated financial statement complete list shareholding present accordance section hgb include audit consolidated financial statement submit german federal gazette ingelheim rhein march boehringer ag board manage director hubertus von baumbach carinne knochebrouillon dr michel pairet jean scheftsik de szolnok michael schmelmer consolidated financial statement independent auditor report independent auditor report ch boehringer sohn ag co kg ingelheim rhein qualified audit opinion consolidated financial statement audit opinion group management report audit consolidated financial statement ch boehringer sohn ag co kg ingelheim rhein subsidiary group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement change group equity financial year january december note consolidated financial statement include recognition measurement policy present addition audit group management report ch boehringer sohn ag co kg financial year january december opinion basis knowledge obtain audit effect matter describe section basis qualified audit opinion consolidated financial statement audit opinion group management report accompany consolidated financial statement comply material respect requirement german commercial law true fair view asset liability financial position group december financial performance financial year january december compliance german legally require accounting principle accompany group management report provide appropriate view group position material respect group management report consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future development pursuant section sentence hgb handelsgesetzbuch german commercial code declare qualification audit opinion consolidated financial statement mention audit lead reservation relate legal compliance consolidated financial statement group management report basis qualified opinion consolidated financial statement audit opinion group management report contrary section number letter b hgb total remuneration grant member member board manage director pension provision recognize recognize member board manage director disclose note consolidated financial statement conduct audit consolidated financial statement group management report accordance section hgb compliance german generally accept standard financial statement audits promulgate institut der wirtschaftsprfer institute public auditor germany idw responsibility requirement principle describe auditor responsibility audit consolidated financial statement group management report section auditor report inde pendent group entity accordance requirement german commercial professional law fulfil german professional responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion consolidate financial statement group management report oiloftrop tcudorp boehringer ingelheim annual report information management responsible information information comprise annual report ex ception audit consolidated financial statement group management report auditor report opinion consolidate financial statement group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider information materially inconsistent consolidated financial statement group management report audit content knowledge obtain audit appears materially misstate responsibility management consolidated financial statement group management report management responsible preparation consolidate financial statement comply material spect requirement german commercial law consolidated financial statement compliance german legally require accounting principle true fair view asset liability financial position financial performance group addition management responsible internal control accordance german legally require accounting principle determine necessary enable preparation consolidated financial statement free material misstatement fraud error prepare consolidated financial statement management responsible assess group ability con tinue go concern responsibility disclose applicable matter relate go concern addition responsible financial reporting base go concern basis accounting provide actual legal circumstance conflict therewith furthermore management responsible preparation group management report provide appropriate view group position material respect consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future development addition management responsible arrangement measure system consider necessary enable preparation group management report accordance applicable german legal requirement able provide sufficient appropriate evidence assertion group management report consolidate financial statement independent auditor report auditor responsibility audit consolidated financial statement group management report objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error group management report provide appropriate view group position material respect consistent consolidated financial statement knowledge obtain audit complie german legal requirement appro priately present opportunity risk future development issue auditor report include opinion consolidate financial statement group management report reasonable assurance high level assurance guarantee audit conduct accordance section hgb compliance german generally accept standard financial statement audit pro mulgate institut der wirtschaftsprfer idw detect material misstatement misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement group management report exercise professional judgment maintain professional skepticism audit identify assess risk material misstatement consolidated financial statement group man agement report fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit consolidate financial statement arrangement measure system relevant audit group management report order design audit procedure appropriate circumstance purpose express opinion effec tiveness systems evaluate appropriateness accounting policy management reasonableness estimate management relate disclosure conclude appropriateness management use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast signif icant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial state ment group management report disclosure inadequate modify respective opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease able continue go concern oiloftrop tcudorp boehringer ingelheim annual report evaluate overall presentation structure content consolidated financial statement include dis closure consolidated financial statement present underlying transaction event manner consolidated financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle obtain sufficient appropriate audit evidence financial information entity business activity group express audit opinion consolidate financial statement group management report responsible direction supervision performance group audit remain solely sponsible audit opinion evaluate consistency group management report consolidate financial statement conformity german law view group position provide perform audit procedure prospective information present management group management port basis sufficient appropriate audit evidence evaluate particular significant assumption management basis prospective information evaluate proper derivation prospective information assumption express separate opinion prospective information assumption basis substantial unavoidable risk future event differ materially prospective information communicate charge governance matter plan scope time audit significant audit finding include significant deficiency internal control identify audit frankfurt main march kpmg ag wirtschaftsprfungsgesellschaft original german version sign kneisel bernau wirtschaftsprfer wirtschaftsprferin german public auditor german public auditor consolidated financial statement independent auditor report oiloftrop tcudorpbronchial cancer cancer cell microvilli attack tlymphocytesproduct portfolio selection human pharmaceutical respiratory disease cardiovascular metabolic disease oncology disease central nervous system infectious disease animal health livestock swine livestock cattleruminant livestock poultry veterinary public health vph companion animal horse companion animal pet oiloftrop tcudorp boehringer ingelheim annual report respiratory disease respiratory disease common chronic obstruc bronchial asthma tive pulmonary disease copd bronchial asthma prevalent chronic disease frequent bronchial asthma chronic inflammatory disorder cause morbidity premature death worldwide airways inflammation accompany airway hyperresponsiveness lead narrow idiopathic pulmonary fibrosis ipf rare disease airway recurrent episode wheeze breathless severely debilitate ultimately lethal ness cough symptom occur particularly night early hour morning know asthma trigger genetic environmental copd factor eg allergen viral infection unlike copd asthma occur early childhood copd chronic disease lung cause cough present adolescent adult asthma e excessive mucus production dyspnea ulti estimate easytomanage condition mately destroy lung tissue alveolus gas patient asthma experience exchange affect lead limitation symptom receive maintenance therapy put airflow cause shortness breath respira increase risk potentially lifethreatene asthma tory symptom airflow limitation partially exacerbation addition patient adjust daily reversible usually worsen time lead dis live accommodate condition avoid physical ability ultimately death symptom excess exertion daytoday activity negative cough breathlessness main reason copd impact quality life stressful patient lung emphysema chronic bronchitis main manifestation copd copd cause continuous damage lung result ing inhale pollutant primarily cigarette smoke factor need consider includ ing indoor outdoor air pollution course copd disease occur second half human life characterize accelerate loss lung function compare normal age occasional sudden worsen symptom function refer acute exacerbation lead downward spiral worsen symptom inactivity product portfolio human pharmaceutical indication brand name active ingredient maintenance treatment patient copd chronic obstructive spiriva include chronic bronchitis emphysema pulmonary disease spiriva handihaler maintenance treatment associate dyspnoea copd spiriva respimat tiotropium bromide prevention exacerbation addon maintenance bronchodilator treatment patient age year old severe asthma experience severe asthma exacer bation past year piriva respimat approve use asthma eu japan usa country label vary country refer local bronchial asthma spiriva respimat tiotropium bromide product information chronic obstructive spiolto respimat maintenance treatment airflow obstruction pulmonary disease stiolto respimat tiotropium bromide patient chronic obstructive pulmonary disease copd inspiolto respimat olodaterol hydrochloride copd chronic obstructive pulmonary disease maintenance treatment patient chronic copd striverdi respimat olodaterol hydrochloride obstructive pulmonary disease copd combination shortacte anticholin ergic reversible broncho betaadrenergic management reversible spasm associated bronchospasms associate obstructive airway obstructive airway ipratropium bromide disease patient require bron disease combivent respimat salbutamol sulphate chodilator chronic obstructive pulmonary disease copd prevention treatment shortness breath patient chronic obstructive pulmonary disease chronic bronchitis copd mild moderate bronchial asthma adulthood childhood supplement beta bronchial asthma atrovent ipratropium bromide agonist case acute asthma prevention treatment symptom chronic berodual obstructive airway disorder reversible airflow chronic obstructive bronchodual ipratropium bromide limitation bronchial asthma especially airway disorder duovent fenoterol hydrobromide chronic bronchitis emphysema oiloftrop tcudorp boehringer ingelheim annual report respiratory disease continue idiopathic pulmonary fibrosis ipf ssc affect lung cause interstitial lung disease ild know sscild key driver mor ipf chronic progressive lung disease associate tality people ssc account approximately markedly reduce life span affect death people worldwide ipf character ize progressive scar lung tissue loss lung function time development scarred tissue chronic fibrose interstitial lung call fibrosis time tissue thicken stiff disease ild progressive ens scar lung lose ability phenotype idiopathic pulmonary transfer oxygen bloodstream vital organ fibrosis ipf oxygen result individual ipf experience shortness breath rest interstitial lung disease heterogeneous group difficulty cope demand everyday rare condition lung run life limited physical capacity risk develop pulmonary fibrosis fibrosis pathological multiplication connective tissue lead acute ipf exacerbation define rapid deteriora ing usually chronic irreversible scar lung tion symptom lung function day week tissue course interstitial lung disease develop event occur point course progressive fibrose ild lead decline func disease presentation associate tion associate increase morbidity mortality high mortality patient ipf risk acute ipf idiopathic pulmonary fibrosis ipf phenotype exacerbation chronic fibrose ild course disease symp tom similar chronic pfild despite underlie ild diagnosis average ild patient systemic sclerosis associate interstitial develop progressive pulmonary fibrosis lung disease sscild systemic sclerosis ssc know scleroderma rare incurable autoimmune disease affect connective tissue disease estimate affect people europe million worldwide ssc impact time woman man onset disease typically occur young age year cause scar fibrosis skin major organ heart lung digestive tract kidney lifethreatene complica tion approximately patient develop significant pulmonary involvement year diagnosis product portfolio human pharmaceutical indication brand name active ingredient symptomatic treatment acute asthma attack prophylaxis exerciseinduce asthma bronchiale symptomatic treatment allergic non allergic asthma bronchiale condition reversible airway narrow eg chronic obstructive bronchial asthma berotec fenoterol hydrobromide bronchitis bronchial asthma prophylactic treatment patient bronchial asthma prophylaxis symptomatic treatment allergic rhinitis alesion epinastine hydrochloride allergic rhinitis idiopathic pulmonary fibrosis ipf country treatment systemic sclerosis patient idiopathic pulmonary fibrosis ipf associate interstitial lung disease sscild country therapy sscild slow rate decline pulmonary function chronic fibrose interstitial lung disease countrie treatment ild progressive chronic fibrose interstitial lung disease ild phenotype ofev nintedanib progressive phenotype ipf oiloftrop tcudorp boehringer ingelheim annual report cardiovascular etabolic disease cardiovascular disease cv include heart disease atrial fibrillation stroke major global health concern lead cause death disability worldwide currently atrial fibrillation af common sustained heart responsible nearly death worldwide rhythm condition affect approximately total key risk factor develop cardiovascular disease population adult develop af presence diabete people type diabete lifetime patient af high risk develop time likely develop cardiovascular disease blood clot upper leave heart chamber people diabete result life cause stroke clot break loose travel expectancy year shorter proper control brain af lead fivefold increase risk stroke diabete treatable risk factor like heart failure result million patient worldwide suffer vital prevention cardiovascular event afrelate stroke year patient af risk stroke reduce appropriate anticoagulation therapy stroke stroke rapidly develop loss brain function prevention treatment caused disrupt blood flow affect brain venous thromboembolism tissue ischemia lack blood supply cause thrombosis embolism bleed venous thromboembolism vte umbrella term hemorrhagic stroke result affect area encompass deep vein thrombosis dvt pulmo brain unable function damage quickly nary embolism pe dvt occur thrombus blood come permanent untreated stroke acute event clot form deep vein commonly leg require emergency diagnosis intervention world partially completely blocks flow blood wide stroke lead cause death thrombus grow portion break away main longterm disability clot travel circulatory system lung lodge blood clot artery lung call symptom transient ischemic attack tia similar pe vte disorder potentially fatal con stroke minute hour sequence result permanent neurological damage tia precede stroke emergency medical care subse patient undergo orthopedic surgery consider quent preventive treatment necessary able risk develop dvt chronic venous insuffi ciency pulmonary hypertension develop long term product portfolio human pharmaceutical indication brand name active ingredient prevention stroke blood clot patient atrial fibrillation stroke prevention primary prevention venous thrombo embolic atrial fibrillation event vte adult elective total hip knee replacement surgery primary prevention venous thromboembolic treatment deep vein thrombosis dvt event orthopedic pulmonary embolism pe secondary prevention surgery recurrent dvt pe adult treatment secondary pradaxa treatment venous thromboembolic event vte prevention venous pradaxar prevention recurrent vte pediatric patient thromboembolic event prazaxa dabigatran etexilate birth year age praxbind specific reversal agent dabigatran indicate adult patient treat pradaxa dabigatran etexilate rapid reversal specific reversal anticoagulant effect require emergency pradaxa surgery urgent procedure lifethreatene dabigatran etexilate praxbind idarucizumab uncontrolle bleed treatment hypertension reduction risk myocardial infarction heart attack stroke death cardiovascular cv cause patient year age old high risk develop major cv event unable ace inhibitor reduction cardiovascular morbidity patient manifest atherothrombotic cardiovascu hypertension lar disease history coronary heart disease stroke peripheral arterial disease patient type cardiovascular morbidity diabetes mellitus document target organ mortality prevention micardis telmisartan damage eu treatment hypertension antihy pertensive agent low blood pressure lower blood pressure reduce risk fatal nonfatal cardiovascular event primarily stroke myocar dial infarction indicate initial therapy micardisplus treatment essential hypertension micardi plus micardisplus fix dose combination indicat micardis hct ed adult blood pressure adequately hypertension comicardis telmisartan hydrochlorothiazide control telmisartan eu oiloftrop tcudorp boehringer ingelheim annual report cardiovascular etabolic disease continue prevent vte event consequence acute myocardial infarction thopedic surgery patient receive kind thromboprophylaxis patient suffer acute myocardial infarction heart attack occur vte require anticoagulant treatment secondary thrombus blood clot suddenly prevent blood prevention recurrent thromboembolic event flow area heart muscle blood flow restore quickly affect section heart muscle permanently damage heart attack reverse anticoagulation common cause death industrialized coun try anticoagulation therapy offer important benefit pa tients risk thromboembolic event rare situation rapid reversal anticoagulation medically necessary eg patient take anticoagulant involve severe car accident need emergency surgery hypertension cardiovascular disease hypertension high blood pressure chronic disease blood pressure chronically elevate hyper tension major risk factor stroke heart attack heart failure chronic renal failure primary goal antihypertensive treatment prevent cardiovascular event reduce risk cardio vascular mortality product portfolio human pharmaceutical indication brand name active ingredient treatment hypertension antihy pertensive agent initial therapy patient likely need multiple antihypertensive agent achieve blood pressure goal twynsta addon therapy adult patient adequately micamlo control blood pressure amlodipine replace micardis amlo ment therapy adult patient receive telmisartan hypertension micardis duo telmisartan amlodipine amlodipine separate tablet eu acute ischemic stroke acute myocardial infarction acute massive pulmonary embolism fibrinolytic treatment acute ischemic stroke acute catheter clearance actilyse myocardial infarction acute massive pulmonary thrombotic occlusion actilyse cathflo alteplase embolism fibrinolytic treatment occlude catheter secondary prevention stroke transient prevention stroke follow initial stroke ischemic attack tia aggrenox dipyridamole acetylsalicylic acid transient ischemic attack tia acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocardial infarction oiloftrop tcudorp boehringer ingelheim annual report cardiovascular etabolic disease continue diabete heart failure cardio renalmetabolic system type diabetes chronic progressive condition asso ciate elevated blood sugar level people type diabete high burden comorbiditie risk factor include heart failure kidney disease hyper tension obesity cardiorenalmetabolic condition affect billion people worldwide lead cause death heart failure progressive debilitate potentially fatal condition occur heart sup ply adequate circulation meet bodys demand oxygenate blood require increase blood volume lead fluid accumulation congestion lung peripheral tissue widespread condition affect million people worldwide expect increase population age collaborative multidisciplinary team approach op timize patient care coordinating treatment relate comorbiditie include use emerge medication broad cardiovascular renal metabolic effect help improve outcome people chronic condition product portfolio human pharmaceutical indication brand name active ingredient treatment adult type diabete mellitus adjunct diet exercise improve glycemic control reduce risk cardiovascular death adult type diabete mellitus establish cardiovascular disease jardiance indication december label vary type diabete mellitus jardianz empagliflozin country refer local product information treatment adult heart failure reduce ejection fraction type diabete jardiance label vary country refer local heart failure jardianz empagliflozin product information treatment adult type diabete mellitus adjunct diet exercise improve glycemic control treatment empagliflozin synjardy metformin appropriate jardiance duo jardianz duo empagliflozin indication december label vary type diabete mellitus synjardy xr metformin hydrochloride country refer local product information treatment adult type diabete mellitus adjunct diet exercise improve glycemic control adult type diabete mellitus empagliflozin linagliptin appropriate treatment glyxambi tradiance empagliflozin indication march label vary country type diabete mellitus jardianz dpp linagliptin refer local product information trajenta treatment adult type diabete mellitus tradjenta adjunct diet exercise improve glycemic trazenta control mono therapy metformin tol type diabete mellitus trayenta linagliptin erate contraindicated combination therapy jentadueto treatment adult type diabete mellitus trayenta duo adjunct diet exercise improve glycemic trajenta duo control treatment metformin lead trajentamet sufficient control patient treat type diabete mellitus jentadueto xr linagliptin metformin hydrochloride trajenta linagliptin metformin diabetes portfolio collaboration eli lilly company oiloftrop tcudorp boehringer ingelheim annual report oncology cancer threat global health estimate million new case cancer diagnose worldwide million people die cancer nearly global death world cancer factsheet common diagnose cancer type lung cancer nearly breast cancer nearly colorectal cancer prostate cancer stomach cancer lung cancer lung cancer refer malignant abnormal cell growth lung tissue common cancer estimate million new case year worldwide smoking primary cause disease contribute case recently incidence lung cancer nonsmoker increase lung cancer poor prognosis million death year represent nearly cancer death lung cancer symptom unspecific disease year appear late diagnosis advanced stage disease result dismal prognosis lung cancer patient survive year follow diagnosis different subtype small cell lung c ancer sclc nonsmall cell lung cancer nsclc different molecular genetic aberration mu tation present tumor identify focus molecular change specific respective subtype lung cancer target therapy effective treatment survival benefit time harmful normal cell reduce effect product portfolio human pharmaceutical indication brand name active ingredient firstline treatment adult patient locally advanced metastatic nonsmall cell lung cancer nsclc tumor activate epidermal growth factor receptor egfr mutation treatment patient locally advanced nonsmall cell lung giotrif metastatic nsclc squamous histology progress cancer nsclc gilotrif afatinib platinumbase chemotherapy combination therapy docetaxel treatment adult patient locally advanced metastatic locally recurrent nonsmall cell lung cancer nsclc nonsmall cell lung adenocarcinoma tumor histology firstline cancer nsclc vargatef nintedanib chemotherapy oiloftrop tcudorp boehringer ingelheim annual report disease central nervous system mental neurological disease depression restless leg syndrome rls parkinson disease significantly impact patient family substantial burden society rls common neurological disorder characterize uncontrollable urge leg primarily occur ring evening night hour usually accom parkinson disease panie unpleasant painful sensation leg disturb sleep result daytime parkinson disease pd degenerative disorder tiredness sleepiness sensation feel deep central nervous system patient usually notice motor leg describe creep crawl ache symptom like hand shake tremor sign disease progress include shake arm leg head motor symptom devel op time include stiffness result loss facial expression gradual slow loss motion freeze patient suffer nonmotor symptom associate pd depre sion sleep disorder primary symptom result lack neurotransmitter dopamine dis tinct area human brain infectious disease hiv infection aid acquire immune deficiency syndrome aid set symptom infection result damage human immune system cause human immunodefi ciency virus hiv untreated infection hiv progre sively reduce effectiveness immune system leave individual susceptible opportunistic infection tumor baby infect mother risk ting virus pregnancy childbirth breastfeed product portfolio human pharmaceutical indication brand name active ingredient sifrol mirapex parkinson disease pd mirapexin symptomatic treatment idiopathic p arkinson pexola pramipexole disease monotherapy com restless leg syndrome mirapex er pramipexole dihydrochloride bination levodopa symptomatic treatment rls sifrol er monohydrate idiopathic moderate severe restless leg syndrome shortterm treatment disorder initiate maintain sleep sleep disorder lendormin brotizolam insomnia require pharmacological ntervention indication brand name active ingredient combination therapy hiv infection country prevention motherto child transmission hiv pregnant woman take antiretroviral therapy time labor viramune prolong release tablet oncedaily dose hiv aids viramune xr nevirapine combination therapy indicate combination antiretroviral treatment hiv infect patient co administer mg ritonavir treatmentexperience infect hiv strain resistant hiv aids aptivus tipranavir protease inhibitor oiloftrop tcudorp boehringer ingelheim annual report livestock swine infectious respiratory disease integrate health management ihm ingelvac circoflex singledose piglet vac farmera soundtalk empower pig cine control porcine circovirus disease pcvd producer breeder retailer consumer improve ingelvac circoflex contain impranflex adjuvant health animal welfare efficiency give insight allow fresh mix ingelvac mycoflex prediction recommendation ihm solu form flexcombo twistpak system tion ingelvac prrs product license active immu nization respiratory reproductive form porcine reproductive respiratory syndrome prr infectious enteric disease enterisol ileitis oral live vaccine ileitis globally prevalent enteric disease swine cause lawsonia intracellularis license improve weight gain reduce growth variability associate disease enterisol ileitis help reduce total antimicrobial use pork production product portfolio animal health indication brand name active ingredient active immunization pig age week porcine circovirus type reduce mortality clinical sign include weight loss lesion lymphoid tissue associate porcine circovirus disease pcvd addition vaccination show reduce pcv nasal shed viral infectious respiratory recombinant vaccine load blood lymphoid tissue duration disease ingelvac circoflex porcine circovirus type pcv viremia ingelvac prrs mlv depend product active immuniza infectious respiratory ingelvac prrsflex eu attenuate live vaccine tion pig age porcine reproduc disease reprocyc prrs eu prrs virus type type tive respiratory syndrome virus prr active immunization pig age infectious respiratory inactivated vaccine week reduce lung lesion follow infec disease ingelvac mycoflex mycoplasma hyopneumoniae tion mycoplasma hyopneumoniae active immunization pig age week intestinal lesion cause law sonia intracellularis infection reduce growth infectious attenuate live vaccine variability loss weight gain associate enteric disease enterisol ileitis lawsonia intracellularis disease soundtalk sound monitor technology sound monitor gateway detect early symptom respiratory distress respiratory disease soundtalk algorithm swine thank monitor algorithm farmera allow efficient effective mobile app digital datum manage proactive enable evidencebase decision make datum capture form ment communication platform realtime information manage health tool farmera swine production production production company soundtalk trademark soundtalk nv oiloftrop tcudorp boehringer ingelheim annual report livestock cattle ruminant cattle ruminant business global leader anti parasitic brand ivomec longrange eprinex world renowne parasiticide treat protect graze animal harmful effect internal external parasite zactran treat cattle bacterial pneumonia sheep digital dermatitis infection bovela active immunization cattle month age term reproductive infectious disease product portfolio animal health indication brand name active ingredient depend formulation product internal external treatment nematode lice mite tick fly lung parasite cattle ivomec ivermectin worm liver fluke theraphase technology develop formulation eprinomectin allow single treatment day long break parasite life cycle effectively reduce parasite burden pasture longrange effective control internal external parasite internal external cattle gastrointestinal roundworm lungworm parasite cattle longrange eprinomectin longacte grub mite depend formulation product internal external treatment nematode lice mite tick fly parasite ruminant eprinex eprinomectin lungworm cattle sheep depend specie indication country reg istration product treatment meta bacterial cause phylaxis control respiratory disease cattle cause respiratory disease key bacteria mannheimia pasteurella histophilus interdigital dermatitis mycoplasma footrot disease sheep cause footrot zactran gamithromycin key bacteria fusobacterium dichelobacter reduce hyperthermia minimize reduction leukocyte count cause bovine viral diarrhoea virus bvdv bvdv reduce virus shed viremia cause bvdv prevent birth reproductive infectious bovine viral diarrhoea bvd persistently infect calf cause transplacental disease cattle bovela type infection oiloftrop tcudorp boehringer ingelheim annual report livestock cattle ruminant continue vaccine pyramidpresponse ex pande portfolio respiratory reproductive vaccine prevent disease affect livestock metacam nonsteroidal antiinflammatory drug nsaid help minimize loss inflammation tissue damage animal suffer disease address need maintain profitability concern farm animal wellbee product portfolio animal health indication brand name active ingredient family multivalent vaccine combi nation include different modify live virus bovine viral diarrhoea pyramidpresponse family vaccine bvd type infectious bo provide broad coverage bvd type ibr vine rhinotracheitis ibr parainflu brsv pi mannheimia haemolytica enza pi bovine respiratory single dose contain metastim adjuvant syncytial virus brsv bacteria system enhance animal response great pasteurella multocida mannheimia protection canada infectious respiratory haemolytica l canicola l grippoty disease reproduc pyramid phosa l hardjo l icterohaemmor metastim register trademark tive disorder cattle presponse rhagiae l pomona zoetis service llc treatment mastitis lactate cow control pain associate dehorning surgery indicate use calf affect pain inflammatory diarrhoea cattle suffer respiratory disorder metacam meloxicam disease oiloftrop tcudorp boehringer ingelheim annual report livestock poultry poultry vaccine portfolio consist significant range live inactivate vectore vaccine broil er layer breeder hen provide protection acute viral bacterial disease like avian influ enza infectious bronchitis newcastle disease infectious bursal disease egg drop syndrome avian coryza portfolio preventive solution help producer world wide provide safe affordable abundant sustainable highquality poultry meat egg product portfolio animal health indication brand name active ingredient monovalent polyvalent attenuate live inactivated vaccine contain ing antigen vaccination avian influenza newcastle disease vaccination healthy chicken disease avian coryza egg drop syndrome caused include antigen prevention viral gallimune infectious bronchitis infectious common disease broiler chicken bacterial disease gallivac bursal disease avian rhinotracheitis disease responsible loss egg production poultry volvac salmonella gallibacterium anatis layer serotype live marek disease infectious bursal disease vector live vhvt recombinant vaccination dayold embryo ibd marek disease virus contain gene ibd dayold chicken effective standard md newcastle dis vaxxitek hvt ibd virus trivalent vaccine variant infectious bursal disease marek disease ease nd infectious vaxxitek hvt ibd nd gene ibd virus nd ilt trivalent vaccine newcastle disease laryngotracheitis ilt vaxxitek hvt ibd ilt virus diluent infectious laryngotracheitis broiler chicken day age active immu nization newcastle disease reduce mortality clinical sign associate disease future layer future breeder pullet age week prime active immunization egg drop cause newcastle disease vacci live newcastle disease virus nation inactivated vaccine strain ulster c newcastle desease nd avinew vg gaavinew strain prior beginning lie prevexxion rn prevexxion rnhvt prevexxion rnhvtibd live herpe virus chimera vaccination dayold embryo prevexxionrn serotype strain rn onedayold chicken recommend protect marek disease vaxxitek hvtibd diluent virulent marek disease live marek disease vectore virus serotype contain gene vaccination dayold embryo newcastle marek insert newcastle disease dayold chicken effective marek disease disease newxxitek hvt nd diluent newcastle disease oiloftrop tcudorp boehringer ingelheim annual report veterinary public health vph work government private partner improve control eradicating disease footandmouth disease bluetongue virus rabie footandmouth fmd vaccine portfolio include aftopor aftovaxpur aftovax provide active immunization cattle sheep pig reduce clinical sign mortality follow exposure fmd virus rabisin inactivated vaccine rabie available clear colorless suspension injection raboral vrg oral recombinant vaccine pro tect wildlife rabie btvpur alsap multistrain vaccine active immunization sheep cattle prevent viremia reduce clinical sign cause bluetongue virus product portfolio animal health indication brand name active ingredient aftopor aftovaxpur highly potent vaccine purify antigen recommend endemic emergency situation potential marker property allow differentiation infect vaccinated animal diva aftovax lowcost effective vaccine profile cattle sheep suitable mass vaccination aftopor endemic situation aftovaxpur mix inactivated fmd virus footandmouth disease aftovax antigen wide range aftovaxpur doe suitable emergency situa fmd aftovaxpur doe vaccine strain tion rabisin active immunization dog cat reduce mortality clinical sign rabie infection immunity demonstrate month vaccination show persist booster dose year primary vaccination year follow booster vaccination raboral vrg oral rabie recombinant vaccine protect wildlife raccoon foxes rabisin inactivated adjuvanted coyote rabie reduce risk rabie virus exposure rabie human domestic animal rabisin raboral vrg vacciniavectored sell government agency conduct rabie raboral vrg rabie vaccine rabie control program active immunization sheep prevent viremia reduce clinical sign cause bluetongue virus serotype combination maximum serotype active immunization cattle prevent viremia cause bluetongue virus serotype reduce clinical sign cause bluetongue virus serotype combination maximum serotype onset immunity demonstrate week week sheep btv primary vaccination course btv btv cattle bluetongue btvpur alsap mix inactivated bluetongue virus btv btv serotype oiloftrop tcudorp boehringer ingelheim annual report companion animal horse equine portfolio highly comprehensive covering eqvalan duogold zimecterin gold combine key aspect equine health include parasite control ivermectin praziquantel ingredient specifically vaccination management chronic disease control tapeworm range flagship market lead equine prod uct recently enhance joint disease articell forte world license veterinary respiratory portfolio addition new innovative stem cell product readytouse intraarticular product line nutraceutical injection chondrogenic induce mesenchymal cell buy prescription treatment lameness link noninfective joint flammation horse articell forte prascend indicate treatment pituitary par late addition equine portfolio available intermedia dysfunction ppid know range country eu equine cushings disease clinical sign ppid hyper trichiosis laminitis change body conformation lack aservo equihaler inhalation product performance treatment prascend lifelong treatment severe equine asthma product novel glucocorticoid prodrug ciclesonide inhalation vetera vaccine vaccine portfolio solution deliver inhaler specifically design clude multiple convenient combination disease pro use horse implement soft technology tection horse young month age derive respimat inhaler human pharma vaccine protect infectious exciting new introduction gain final authorization organism include influenza herpe west nile virus product availability eu canada tetanus enable customize protection approval country expect horse limited needle injection course gastrogardulcergard indicate treat ment prevention equine gastric ulcer common disease horse gastrogard supply easytouse oral paste form choice treatment gastric ulcer launch ulcergard preventive choice horse increase risk develop gastric ulcer eqvalanzimecterin contain ivermectin lead ingredient control wide variety important inter nal parasite include bot benzimidazoleresist ant small strongyle easytoadminister oral paste eqvalanzimecterin approve adult horse foal young week age product portfolio animal health indication brand name active ingredient symptomatic treatment clinical sign associate pituitary par intermedia pituitary par intermedia dysfunction ppid dysfunction ppid prascend pergolide mesylate know equine cushing disease eastern western venezuelan combination vaccine encephalomyelitis tetanus west nile vaccination healthy horse aid pre com virus equine herpe virus equine vention disease caused include antigen mon disease horse vetera influenza viruse canada treatment prevention gastric ulcer gastrogard prevention recurrence gastric ulcer horse equine gastric ulcer ulcergard omeprazole foal week age old eqvalan treatment prevention parasitic infestation zimecterin horse donkey large small stron eqvalan gold gyle ascarid eqvalan duo ivermectin internal parasites zimecterin gold ivermectin praziquantel goldduo include treatment tapeworm treatment mild moderate lameness link noninfective joint inflammation horse contain reduction mild stem cell obtain equine blood moderate recurrent stem cell develop type cell lameness associate chondrogenic induce equine stem cell active substance mesenchymal stem nonseptic joint allogeneic peripheral bloodderive cell treat develop cartilage inflammation horse articell forte mesenchymal stem cell cell alleviation clinical symptom severe equine asthma characterize cough nasal discharge nasal flare increase breathing effort severe equine asthma aservo equihaler ciclesonide inhalation solution rest abnormal lung sound oiloftrop tcudorp boehringer ingelheim annual report companion animal pet pet portfolio offer diverse solution broadline recently launch nexgard combo important need canine feline health includ offer cat owner allinone convenience provide confi ing industryleade parasiticide vaccine pain therapy dence cat broad possible protection therapeutic address major chronic disease heart protect cat broadest spectrum internal failure kidney disease hypertension epilepsy diabete external parasite include flea tick heartworm mellitus osteoarthritis hookworm roundworm lungworm vesical worm tapeworm year frontline leader flea tick control dog cat trust boehringer ingelheim complete trust ed brand animal health frontline continue prove range product service pain man bring innovation category recent launch agement choose portfolio give veterinarian frontline shield feature repellency freedom tailor treatment patient provide insecticidal efficacy diseasecarrye fly access valueadde veterinary service insect decrease risk transmission vectorborne pathogen metacam offer extensive range formulation indication make complete nonsteoridal anti nexgard contain active ingredient afoxolaner inflammatory drug nsaid dog cat guinea launch oral medication pig enable veterinarian well achieve goal treat flea tick dog efficacy pain management give owner pet exactly palatable beefflavore soft chew formulation product need ample longterm study support nexgard currently bestselle pet medication product safety efficacy lead multiple animal health industry indication diverse specie nexgard spectra combine flea tick efficacy liquid formulation metacam dog make afoxolaner nexgard broadspectrum de easy titrate low effective dose liquid worming ingredient milbemycin oxime formulation cat easy administer improve beefflavore chew nexgard spectra ef dog administration syringe aim achieve well accu fective treating flea tick mite infestation racy introduce gastrointestinal parasite infection protect dog deadly parasites heartworm lung worm heartgard plus contain active ingredient ivermectin pyrantel soft beef chew give monthly ivermectin effective prevent heartworm disease pyrantel effective treatment control roundworm hookworm heartgard datum file b abesia canis transmit dermacentor reticulatus tick ehrlichia launch monthly heartworm canis transmit rhipicephalus sanguineus tick leishmania preventative bestselle heartworm pre infantum transmit phlebotmine sandfly datum file ventative world datum file product portfolio animal health indication brand name active ingredient frontline plusfrontline combo indicate treatment prevention flea tick lice infestation break flea life cycle pre venting development flea immature stage frontline frontline triactfrontect frontline frontline combo shield indicate treatment pre frontline plus vention flea tick infestation dog frontline triact fipronil provide repellent activity mosquito antiparasitic canine frontect fipronil smethoprene sandfly tick reduce risk transmission feline external parasite frontline shield fipronil permethrin pyriproxifen vectorborne pathogen nexgard highly palatable beefflavored chew indicate treatment prevention flea tick infestation dog indicate prevention borrelia burgdorferi infections antiparasitic canine treatment demodex sarcopte external parasite nexgard afoxolaner otodecte mite infestation nonus geography nexgard spectra deliver highly palatable beefflavored chew indicate treatment prevention flea tick mite infestation antiparasitic canine prevent heartworm disease angiostrongylosis internal external thelaziosis treat hookworm roundworm parasite nexgard spectra afoxolaner milbemycin oxime whipworm infestation dog use dog prevent canine heartworm disease eliminate tissue stage heartworm larvae antiparasitic canine month day infection treat internal parasite heartgard plus ivermectin pyrantel ment control roundworm hookworm protect cat broadest spectrum internal external parasite include adult flea antiparasitic feline flea eggs flea larvae tick heartworm lungworm internal external fipronil smethoprene hookworm roundworm vesical worm tape parasite broadline eprinomectin praziquantel worms spoton formulation contain esafoxolaner provide new generation flea tick control cat protect cat broadest spectrum antiparasitic feline internal external parasite include flea tick internal external esafoxolaner eprinomectin ear mite heartworm lungworm hookworm parasite nexgard combo praziquantel roundworm vesical worm tapeworm metacam reduce specific type pain inflammatory postoperative pain inflammation disease metacam meloxicam musculoskeletal disorder dog cat oiloftrop tcudorp boehringer ingelheim annual report companion animal pet continue previcox design specifically dog launch prozinc proven selective veterinary cox inhibitor previcox insulin choice feline patient owner con provide safe sustained pain relief fast onset ac venient management feline diabete approval tion longterm safety efficacy establish prozinc canine patient opportunity large field study previcox shown firstchoice solution successful man efficacious competition acute model agement diabete dog cat large clinical osteoarthritis study europe japan confirm majority dog manage injection vetmedin inodilator stan prozinc insulin day major breakthrough dard care treat dog congestive heart dog owner veterinarian failure caused dilate cardiomyopathy valvular sufficiency mitral tricuspid regurgitation pet vaccine product portfolio include purevax combination furosemide significantly m feline vaccine formulate provide effective protection prove clinical sign extend life expectancy use adjuvant catfriendly patient recent study show vaccination purevax launch reduce preclinical asymptomatic case dilate cardio ml volume france myopathy doberman pinschers valvular insufficiency recombitek offer complete line advanced canine vetmedin significantly delay onset clinical sign vaccine provide target protection recombi congestive heart failure veterinary cardiology nant technology rabisin imrab provide trust vaccine fight rabie decade prove semintra firstever license angiotensin receptor efficacy safety blocker veterinary use specifically design cat semintra scientifically advanced treatment simple solution safely effectively harness protective benefit cat reninangiotensin aldosterone system protect kidney key organ semintra available mgml mgml oral solution semintra mgml launch reduction proteinuria associated chronic kidney disease cat semintra mgml launch control treatment eu feline systemic hypertension vetlicense product feline hypertension product portfolio animal health indication brand name active ingredient relief pain inflammation associate pain inflammatory osteoarthritis specific type disease previcox firocoxib postoperative pain dog treatment canine congestive heart failure originat ing dilate cardiomyopathy valvular insuffi ciency mitral tricuspid regurgitation treatment dilate cardiomyopathy preclinical stage asymptomatic increase leave ventricu lar endsystolic enddiastolic diameter doberman pinscher treatment dog myxomatous mitral valve disease mmvd preclinical stage asympto matic systolic mitral murmur evidence increase heart size delay onset clinical congestive heart failure vetmedin pimobendan symptom heart failure chronic kidney disease ckd cat management chronic kidney disease ckd hypertension cat semintra telmisartan feline systemic hypertension eu cat treatment diabete mellitus cat dog achieve reduction hyperglycemia improve diabete prozinc protamine zinc ment associate clinical sign feline herpe virus feline calicivirus feline panleukopenia virus chlamydia purevax fully adjuvantfree feline felis recombinant vectore feline vaccine range leverage innovative canarypox leukemia virus recombinant vectore technology felv rabie offer sustained feline vaccine portfolio purevax rabies virus protection rabie year recombinant vectore caninedistem virus canine parvovirus canine recombitek feature complete line canine adenovirus type canine parain vaccine include fluenza virus canine coronavirus leptospira canicola leptospira recombitek lyme vaccine contain grippotyphosa leptospira ictero ospa nonadjuvant formulation haemorrhagiae leptospira pomona canine vaccines recombinant borrelia burgdorferi recombitek oral bordatella effective safe portfolio rekombitek bordetella bronchiseptica protection easy sustained rabie protection year rabie vaccine rabisin inactivated adjuvante year booster consistently high seroconversion portfolio imrab rabie glycoprotein rate rabie protection specie oiloftrop tcudorpch boehringer sohn ag co kg ingelheim rhein comparison balance sheet financial data asset december million eur intangible asset tangible asset financial asset fix asset inventory account receivable asset incl prepay expense defer taxis exceed plan asset financial fund current asset total asset equity liability december million eur shareholder capital group reserve incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolle interest group equity difference capital consolidation provision incl defer taxis liability incl defer income total liability incl defer taxis defer income total equity liability summary select financial datum million eur net sale operating income operating income net sale income taxis income taxis net sale equity ratio cash flow operating activity financial fund personnel expense personnel expense net sale average number employee research development expense rd net sale investment tangible asset depreciation tangible asset imprint asset december ch boehringer sohn ag co kg million eur binger strasse intangible asset ingelheim rhein tangible assets germany financial asset telephone fax fix asset inventory contact account receivable asset incl prepay expense corporate affair defer taxis exceed plan asset matthia reinig financial fund pressboehringeringelheimcom current asset boehringeringelheimcom total asset issue equity liability december ch boehringer sohn ag co kg represent board manage director million eur hubertus von baumbach chair shareholder capital carinne brouillon dr michel pairet group reserve incl balance sheet currency conversion difference jean scheftsik de szolnok michael schmelmer group profit concept design layout equity attributable parent company st kommunikation gmbh mainz noncontrolle interest wwwstde group equity difference capital consolidation photo provision incl defer taxis andreas reeg page lennart nilsson page getty image liability incl defer income total liability incl defer taxis defer income print total equity liability eberl koesel gmbh co kg altusriedkrugzell summary select financial datum copyright ch boehringer sohn ag co kg million eur right reserve annual report reproduce trans net sale mitte form mean electronic photocopy permission operating income writing ch boehringer sohn ag co kg figure party operating income net sale annual report base datum available time financial statement draw income taxis income taxis net sale equity ratio cash flow operating activity financial fund personnel expense personnel expense net sale average number employee research development expense rd net sale investment tangible asset co emission certificate support forest conservation depreciation tangible asset forest modification region germanyboehringeringelheimcom annualreportboehringeringelheimcom troper launna miehlegni regnirheob